

## **Michael A. Horberg, MD, MAS, FACP, FIDSA**

Associate Medical Director

Areas of Responsibility: Research, Medical Education, Community Health, Medicaid, Genetics,  
HIV & STI, Transgender Health, Complex Care Program, Infection Prevention  
Mid-Atlantic Permanente Medical Group PC

Work Address: 2101 East Jefferson Street, 3 East, Rockville, MD 20852

Telephone: 301-816-6302

Email: [michael.horberg@kp.org](mailto:michael.horberg@kp.org)

---

### **VERBAL INTRODUCTION**

---

**Michael Alan Horberg, MD, MAS, FACP, FIDSA** is Associate Medical Director for Kaiser Permanente Mid-Atlantic Permanente Medical Group (KPMAS MAPMG), serving greater Baltimore and District of Columbia, suburban Maryland and northern Virginia. In that role, he is responsible for Research, Medical Education, Community Health, Medicaid, Genomics, HIV and STI, Complex Care, LGBTQI+ Health and Infection Prevention.

Dr. Horberg is the director of HIV/AIDS nationally for KP, serving nearly 80,000 members with HIV, as well as Clinical Lead for HIV/AIDS and STI, creating clinical multidisciplinary guidelines to improve such care in KP. He has chaired the KP HIV, Liver Disease, STI, and LGBTQ Health Conference since 2003, bringing together clinical and research staff to ensure best practices.

Under President Obama, Dr. Horberg served on the Presidential Advisory Council on HIV/AIDS (PACHA), and co-chaired the Access to Care and Improved Outcomes Committee. Dr. Horberg is a Fellow of the American College of Physicians and the Infectious Disease Society of America (IDSA). He is Past-Chair of the Board of Directors of the HIV Medicine Association (HIVMA). He has served on the IDSA Quality Performance Committee, and presently co-chairs the HIVMA/IDSA HIV Primary Care Guideline Committee. Dr. Horberg presently serves as the physician chair of the CDC-sponsored Health Care Action Group, promoting sexual health. He has chaired multiple Expert Panels on HIV-related provider performance measures (including ones sponsored by CMS, NCQA, and IDSA), and has served on NIH and CDC peer-review panels. He is past-president of the national Gay and Lesbian Medicine Association.

Dr. Horberg leads HIV, STI, and Infection Prevention for MAPMG. He directs LGBTQI+ care and led creation of *Pride Medical* and *Gender Pathways* clinics within KPMAS. In his role as medical director for KPMAS Community Health and chief medical officer for KPMAS Maryland and Virginia Medicaid, he works to improve health equity and care access for underserved populations in the region.

As Executive Director for research, he is responsible for all research in KPMAS. In this role, he leads a department of clinical and data research with over seventy employees. His HIV research interests are HIV quality measures, care improvement, and determinants of optimized multidisciplinary care for HIV-infected patients. He studies epidemiology of HIV, hepatitis, sexually transmitted and COVID infections, leading all hepatitis care programs and COVID efforts in KPMAS. Dr. Horberg has published over 200 manuscripts and delivered over 100 presentations at scientific meetings (all peer-reviewed).

As Director for Medical Education, he is the Designated Institutional Official for KPMAS, with responsibility for all undergraduate, graduate, and continuing medical education. He also leads the KPMAS Medical Genetics and Genomics strategy, and is Executive Sponsor for Commission on Cancer Accreditation and National Surgical Quality Improvement Program.

Dr. Horberg attended Boston University Medical School, and received his Master of Advanced Studies from University of California San Francisco. He completed his residency in internal medicine at University of Chicago Michael Reese Hospital and Medical Center. He is a resident of Maryland, with his husband Chip and their pet poodle Grant.

---

### **EDUCATION AND TRAINING**

---

<i>University of California San Francisco, San Francisco, CA</i> <b>M.A.S. (Master of Advanced Study in Clinical Research)</b>	2004-2006
<i>University of Chicago/Michael Reese Hospital, Chicago, IL</i> <b>Residency, Categorical Internal Medicine</b>	1985-1988
<i>Boston University School of Medicine, Boston, MA</i> <b>M.D.</b>	1981-1985
<i>Boston University, Boston, MA</i> <b>B.A. in Medical Science with Minor in History</b> <i>Summa cum Laude, Phi Beta Kappa</i>	1979-1985

---

## APPOINTMENTS AND EMPLOYMENT

---

<i>Mid-Atlantic Permanente Medical Group, Rockville, MD</i> <i>Mid-Atlantic Permanente Research Institute</i> <b>Associate Medical Director Research, Medical Education, Community Health, Medicaid, Genetics, HIV and STD, LGBTQI+ Health, Complex Care Program, Infection Prevention</b> <b>Executive Director, Mid-Atlantic Permanente Research Institute</b> <b>Designated Institutional Official, Kaiser Permanente Mid-Atlantic States</b>	2011-
<i>Kaiser Permanente and The Permanente Federation, Oakland, CA</i> <i>Care Management Institute</i> <b>Director, HIV/AIDS and Sexually Transmitted Infections</b>	2003-
<i>Kaiser Permanente Institute for Health Policy, Oakland, CA</i> <b>Fellow</b>	2010-2016
<i>The Permanente Medical Group, Inc., Oakland, CA</i> <i>Kaiser Permanente Northern California Division of Research</i> <b>Chair, Central Research Committee</b> <b>Research Scientist II</b> <b>Senior Physician and Research Chair, Santa Clara Medical Center</b>	1997-2011
<i>Private Medical Practice, Chicago, IL</i>	1988-1997

---

## GOVERNMENT SERVICE/ APPOINTMENTS

---

<i>Presidential Advisory Council on HIV/AIDS (PACHA)</i> <b>Presidential Appointment /Special Government Employee</b>	2010-2014
<b>Co-chair, Access to Care and Quality Outcomes Committee</b>	2010-2014
<i>State of Maryland Natalie M. LaPrade Medical Cannabis Commission</i> <b>Member, Commission</b>	2013-2017
<i>CDC Coalition on Sexual Health</i> <b>Chair, Health Care Action Group</b>	2012-
<i>Patient-Centered Outcomes Research Institute (PCORI)</i> <b>Member, PCORnet Engagement Council</b>	2016-2018
<i>Institute for Public Health Innovation</i> <b>Chair, Board of Directors</b>	2018-2020
<b>Member, Board of Directors</b>	2013-2020

<b>Member-at-Large, Executive Committee</b>	2013-2018
<i>University of California Office of the President HIV/AIDS Research Program</i>	
<b>Member, Advisory Council</b>	2009-2011
<i>Visioning Change: State Office of AIDS and University of California HIV Research Program</i>	
<b>Member, Leadership Committee</b>	2009-2010

---

## ACADEMIC APPOINTMENTS

---

<i>Bernard J. Tyson Kaiser Permanente School of Medicine</i>	
<b>Professor</b>	2018-
<i>Stanford University Medical School, Palo Alto, CA</i>	
<b>Clinical Assistant Professor</b> (Affiliated) of Medicine (Infectious Diseases)	2010-2012
<b>Clinical Instructor</b>	1998-2010
<i>Northwestern University Medical School, Chicago, IL</i>	
<b>Clinical Instructor</b>	1988-1996
<i>University of Illinois College of Medicine, Chicago, IL</i>	
<b>Assistant Clinical Professor</b>	1990-1996

---

## BOARD CERTIFICATIONS AND LICENSURE

---

American Board of Internal Medicine	1989-
HIV Specialist Credentials—American Academy of HIV Medicine	2002-
California Medical License (Active)	1996-
District of Columbia Medical License (Active)	2011-
Illinois Medical License (Inactive)	1985-1996
Maryland Medical License (Active)	2011-
Commonwealth of Virginia Medical License (Active)	2011-

---

## PROFESSIONAL AFFILIATIONS AND SERVICE

---

HIV Medicine Association (HIVMA) of the Infectious Disease Society of America	
Chair, Board of Directors	2012-2013
Chair, HIV MOC Committee	2009-2012
Board Member	2007-2014
Infectious Disease Society of America (IDSA)	
Fellow	2011-
Member, IDSA Education Committee	2009-2012
Member, IDSA Research Committee	2012-2014
Member, IDSA Quality Measures Committee	2014-
Co-Chair, HIV Primary Care Guidelines Committee	2016-
American College of Physicians	
Fellow	1997-
Forum for Collaborative HIV Research	
Member, Executive Committee	2006-
Health Care Systems Research Network (formerly HMO Research Network)	
Chair, Board of Directors	2023-2025
Board of Governors	2011-
Executive Committee	2018-
Gay and Lesbian Medical Association (GLMA, 2000 + members nationally)	
President	1997-1998

Gay and Lesbian Physicians of Chicago President	1994-1996
International AIDS Society Academy Health	2002- 2013-
International Association of Physicians in AIDS Care	2008-
American Academy of HIV Medicine (AAHIVM)	2000-2015
California Medical Association	1998-2011
AIDS Community Research Consortium	1997-2010
Bay Area Association of Physicians for Human Rights	1997-2011

---

## SCIENTIFIC REVIEW PANEL ACTIVITIES

---

### National Institutes of Health

Clinical Trial Units for NIAID Networks ZAI1-RB-A-S2	2013
Innovative Research in HIV in Kidney, Urology, and Hematology ZRG1 AARR M54	2016

### Centers for Disease Control and Prevention

HIV Testing Program Sites	2010
---------------------------	------

---

## KAISER PERMANENTE SERVICE (SELECTED APPOINTMENTS)

---

### Kaiser Permanente Interregional

Director, HIV Interregional Initiative Steering Committee	2003-
Clinical Lead, KP HIV Clinical Care Guidelines	1998-
HIV, Hepatitis, and STI National Conference Conference Chair and Director	2004-
Member, Interregional New Technologies Committee	2013-
National Research Committee Chair	2011- 2018-2020

### Kaiser Permanente Northern California Region

Chair, Regional HIV Therapeutics Subcommittee	1998-2011
Health Services Institutional Review Board	2005-2011
Santa Clara Infection Control Committee	1997-2011

---

## EDITORIAL ACTIVITIES

---

### Editorial Board

<i>HIV and Behavior</i>	2019-
<i>The American Journal of Managed Care Evidence-Based Immunology and Infectious Disease</i>	
<i>Annals of the Forum for Collaborative HIV Research</i>	

### Reviewer for the Following Journals:

*AIDS and Behavior*  
*AIDS, Patient Care, and STDs*  
*AIDS Research and Human Retroviruses*  
*American Journal of Kidney Diseases*  
*Annals of Internal Medicine*  
*Archives of Psychiatry*  
*BMC Infectious Diseases*  
*BMC Medical Informatics and Decision Making*  
*BMC Medicine*  
*Clinical Infectious Diseases*  
*HIV Clinical Trials*  
*International Journal of Environmental Research and Public Health*  
*JAIDS*

*Journal of Antimicrobial Chemotherapy*

*Journal of Infection*

*Pediatrics*

*The Permanente Journal*)

Reviewer/Assistant Editor for the following Textbooks:

*LGBTQ America Today: An Encyclopedia*

Reviewer for the following Conferences:

Infectious Disease Society of America Annual Meeting

International AIDS Society International AIDS Conference

National Summit on HIV Diagnosis, Prevention, and Access to Care

---

## MENTORSHIP AND TEACHING

---

Kaiser Permanente Northern California:

David Vinson, MD (Emergency Medicine; CREST Network)

Minggui Pan, MD (Oncology; Community Benefits Clinician Research)

Resident research at Kaiser Permanente Santa Clara Medical Center

Kaiser Permanente Mid-Atlantic States:

Sherri Johnson, RN (Doctoral research)

Jared Maeda, PhD (Health Services research scientist)

Chu-Ling Yu, ScD (Oncology Epidemiology research scientist)

Christine Bredfeldt, PhD (Health Informatics research scientist)

Cabell Jonas, PhD (Health Services research scientists)

Kaiser Permanente Santa Clara Medical Center

Director and Preceptor, HIV Clinic for residents

1999-2010

Primary Care Preceptor in Clinic

1997-2010

Morning Report Attending (twice a month)

1997-2005

Ward Attending in Medicine

1998-2000

---

## SPECIAL RECOGNITIONS

---

*Washington Business Journal* Business of Pride

2020

Mid-Atlantic Permanente Medical Group Excellence in Research Award

2016

City of Oakland, California, Mayor's Proclamation "Michael Horberg Day"

2010

Kaiser Permanente Santa Clara Teacher of the Year

2001, 2002

---

## PUBLICATIONS AND ABSTRACTS

---

*First and senior authored listed first*

### Peer-Reviewed Publications

1. **Horberg M**, Antoniskis D, Bersoff-Matcha S, Hurley L, Klein D, Kovach D, Mogyoros M, Towner W, Weinberg W. Perceptions of human immunodeficiency virus testing services among HIV-positive persons not in medical care. *Sex Transm Dis*. 2006 Jul;33(7):464; author reply 465.
2. **Horberg M**, Hurley LB, Klein DB, Follansbee SE, Quesenberry C, Flamm JA, Green GM, Luu T. Surgical outcomes in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. *Arch Surg*. 2006 Dec;141(12):1238-45.
3. **Horberg M**, Hurley LB, Silverberg MJ, Kinsman CJ, Quesenberry CP. Effect of clinical pharmacists on utilization of and clinical response to antiretroviral therapy. *J Acquir Immune Defic Syndr*. 2007 Apr 15;44(5):531-9.
4. **Horberg MA**, Silverberg MJ, Hurley LB, Towner WJ, Klein DB, Bersoff-Matcha S, Weinberg WG, Antoniskis D, Mogyoros M, Dodge WT, Dobrinich R, Quesenberry CP, Kovach DA. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral

therapy and on clinical outcomes in HIV-infected patients. *J Acquir Immune Defic Syndr*. 2008 Mar 1;47(3):384-90.

5. **Horberg M**, Silverberg M, Hurley L, Delorenze G, Quesenberry C. Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens. *AIDS Patient Care STDS*. 2008 Apr;22(4):301-12.
6. **Horberg M**, Klein D, Hurley L, Silverberg M, Towner W, Antoniskis D, Kovach D, Mogyoros M, Blake W, Dobrinich R, Dodge W. Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients. *HIV Clin Trials*. 2008 Nov-Dec;9(6):367-74.
7. Silverberg MJ, Leyden W, Hurley L, Go AS, Quesenberry CP Jr, Klein D, **Horberg MA**. Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. *Ann Intern Med*. 2009 Mar 3;150(5):301-13.
8. Silverberg MJ, Leyden W, Quesenberry CP Jr, **Horberg M**. Race/Ethnicity and risk of AIDS and death among HIV-infected patients with access to care. *J Gen Intern Med*. 2009 Sep;24(9):1065-72.
9. **Horberg M**, Ranatunga DK, Quesenberry CP, Klein DB, Silverberg MJ. Syphilis epidemiology and clinical outcomes in HIV-infected and HIV-uninfected patients in Kaiser Permanente Northern California. *Sex Transm Dis*. 2010; 37(1): 53-58.
10. Towner W, Klein D, Kerrigan HL, Follansbee S, Yu K, **Horberg M**. Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study. *J Acquir Immune Defic Syndr*. 2009 Aug 1;51(4):367-73.
11. **Horberg M**, Tang B, Towner W, Silverberg M, Bersoff-Matcha S, Hurley L, Chang J, Blank J, Quesenberry C Jr, Klein D. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naïve patients. *J Acquir Immune Defic Syndr*. 2010 Jan 1;53(1):62-9.
12. **Horberg M**, Aberg J, Cheever L, Renner P, Kaluba E, Asch S, "National and Multi-Agency HIV Quality Measures Development," *Clinical Infectious Diseases*, 2010; 51:732-738.
13. **Horberg M**, Klein, D, "An update on the use of Atripla in the Treatment of HIV in the US," *HIV—Research and Palliative Care*, 2010 (2): 135–140.
14. **Horberg M**, Hurley L, Towner W, Gambatese R, Klein D, Antoniskis D, Weinberg W, Kadlecik P, Remmers C, Dobrinich R, Quesenberry C, Silverberg M, Johnson M, "HIV Quality Performance Measures in a Large Integrated Healthcare System," *AIDS, Patient Care, and STDs*, 2011; 25(1): 21-28.
15. Schwarz EB, Postlethwaite D, Hung Y-Y, Lantzman E, Armstrong MA, **Horberg M**, "Provision of Contraceptive Services to Women with Diabetes," *Journal of General Internal Medicine*, 2012 Feb;27(2):196-201
16. Towner W, Xu L, Leyden W, **Horberg M**, Chao C, Tang B, Klein D, Hurley L, Quesenberry C, Silverberg M, "The Effect of HIV Infection, Immunodeficiency and Antiretroviral Therapy on the Risk of Hepatic Dysfunction," *JAIDS*, 2012 Jul 1;60(3):321-7
17. **Horberg M**, Hurley L, Towner W, Allerton M, Tang B, Catz S, Silverberg M, Quesenberry C, "Determination of Optimized Multidisciplinary Care Team for Maximal Antiretroviral Therapy Adherence," *JAIDS*, 2012 Jun 1;60(2):183-90
18. Chao C, Tang B, Hurley L, Silverberg M, Towner, W Preciado M, **Horberg M**, "Risk Factors for Short-Term Virologic Outcomes among HIV-Infected Patients undergoing Regimen Switch of Combination Antiretroviral Therapy," *AIDS Research and Human Retroviruses*, 2012; Dec;28(12):1630-6.

19. **Horberg M**, Hurley L, Towner W, Allerton M, Tang B, Catz S, Silverberg M, Quesenberry C, "Impact of Provider Experience Characteristics on Antiretroviral Adherence and Maximal Viral Control," *HIV/AIDS—Research and Palliative Care*, 2012; 4:125-133
20. **Horberg M**, Raymond B, "Financial Policy Issues for PrEP: Practical Aspects of Cost and Access to Insurance," *American Journal of Preventive Medicine*, 2012 ; 44(1S2):S125–S128
21. Miller V, **Horberg M**, "Getting to Normal -- Are we there yet?" (editorial), *AIDS*, 2013; 27(6):1027-1028
22. **Horberg M**, Hurley L, Klein D, Silverberg M, Quesenberry C, Mugavero M, "Missed Office Visits and Risk of Mortality among HIV Subjects in a Large Healthcare System," *AIDS, Patient Care and STDs*, 2013; 27(8):442-9
23. Aberg J, Gallant J, Ghanem K, Emmanuel P, Zingman B, **Horberg M**, "Primary Care Guidelines for the Management of Persons Infected with Human Immunodeficiency Virus: 2013 Update by the HIV Medicine Association of the Infectious Diseases Society of America," *Clinical Infectious Diseases*, 2014; 58(1):e1-e34.
24. Aberg J, Gallant J, Ghanem K, Emmanuel P, Zingman B, **Horberg M**, "Executive Summary: Primary Care Guidelines for the Management of Persons Infected with Human Immunodeficiency Virus: 2013 Update by the HIV Medicine Association of the Infectious Diseases Society of America," *Clinical Infectious Diseases*, 2014; 58(1):1-10.
25. Linas B, Hu H, Carter D, **Horberg M**, "Hepatitis C screening trends in a large integrated health system," *American Journal of Medicine*, 2014; 127(5):398-405.
26. Althoff K, Rebeiro P, Brooks J, Buchacz K, Gebo K, Martin J, Hogg R, Thorne J, Klein M, Gill MJ, Sterling T, Yehia B, Justice A, Gange S, Moore R, Kitahata M, **Horberg M**, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Disparities in the quality of HIV care when using US Department of Health and Human Services Indicators", *Clinical Infectious Diseases*, 2014; 58(8):1185-9
27. Maeda J, Lee K, **Horberg M**, "Comparative Health Systems Research among Integrated Delivery Systems and Managed Care Organizations: A Systematic Review," *Permanente Medical Journal*, 2014; 18(3):66-77
28. Rodriguez C, **Horberg M**, "HIV Testing, Staging, and Evaluation," *Infectious Disease Clinics of North America*, 2014 Sep;28(3):339-353
29. **Horberg M**, "HIV Quality Measures and Outcomes—The Next Phase," *Clinical Infectious Diseases*, 2016; Jan 15; 62(2):240-1.
30. **Horberg M**, Hurley L, Towner W, Kadlecik P, Antoniskis A, Mogyoros M, Brachman P, Remmers C, Gambatese R, Blank J, Ellis C, Silverberg M, "The HIV Care Cascade Measured Over Time and by Age, Sex, and Race in a Large National Integrated Care System, *AIDS, Patient Care, and STDs*, 2015; 11: 582-590.
31. Jonas MC, Loftus B, **Horberg M**, "The Road to Hepatitis C Virus Cure: Practical Considerations from a Health System's Perspective," *Infectious Disease Clinics of North America*, 2018; 32(2): 418-493.
32. **Horberg M**, Oakes A, Hurley L, Towner W, Chao C, Silverberg M, Chantra J, Ellis C, Quesenberry C, "Association of Raltegravir Use with Long-Term Health Outcomes in HIV-Infected Patients: An Observational Post-Licensure Safety Study in a Large Integrated Healthcare System," *HIV Clinical*

33. **Horberg M**, Blank J, Rubenstein K, Certa J, Hurley L, Kadlecik P, Klein D, Silverberg M, “Impact of Alternative Encounter Types on HIV Viral Suppression Rates in an Integrated Health System,” *AIDS, Patient Care, and STDs*, 2018; 32(11): 425-431.
34. Ter-Minassian M, Lanzkron S, Derus A, Brown E, **Horberg M**, “Quality Metrics and Health Care Utilization for Adult Patients with Sickle Cell Disease,” *Journal of the National Medical Association*, 2018; (e-Pub ahead of print)
35. Rodriguez C, Rubenstein K, Linas B, Hu H, **Horberg M**, “Increasing Hepatitis C Screening in a Large Integrated Health System: Science and Policy in Concert,” *American Journal of Managed Care*, 2018; 24(5): e134-e140.
36. Vupputuri S, Rubenstein K, Derus A, Loftus B, **Horberg M**, “Factors Contributing to Racial Disparities in Influenza Vaccinations,” *PLoS One*, 2019; 14(4): e0213972.
37. George JM, Kuriakose S, Monroe A, Hou Q, Pau A, Masur H, Hadigan C, Castel A, **Horberg M**, on behalf of the DC Cohort Executive Committee, “Utilization of Direct Oral Anticoagulants in People with HIV: Observational Data from the DC Cohort,” *Clinical Infectious Diseases*, 2020; e-pub ahead of print.
38. **Horberg M**, Certa J, Rubenstein K, Hurley B, Satre D, Kadlecik P, Silverberg MJ, “Beyond the HIV Care Continuum and Viral Suppression: Broadening the Scope of Quality Metrics for Total HIV Patient Care,” *AIDS, Patient Care, and STDs*, 2020; Nov;34(11):461-469.
39. Thompson M, **Horberg M** (co-lead authors), Agwu A, Colasanti J, Jain M, Short W, Singh T, Aberg J, “Primary Care Guidance for Persons with Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America,” *Clinical Infectious Diseases*, 2020; Dec 6;73(11):e3572-e3605.
40. Isaac A, Swartz D, Miller M, Short D, Wilson E, Chaffo J, Watson E, Hu H, Petersen B, Bloom J, Neff N, Linders D, Salgado S, Locke J, **Horberg M**, “Lower Resource Utilization of Patients with Healed Diabetic Foot Ulcers During Participation in a Prevention Program with Foot Temperature Monitoring,” *BMJ Open Diabetes Research and Care*, 2020; October 8 (1): e001440.
41. Young D, Sidell M, Fitzpatrick S, Koebnick C, Nau C, Oshiro C, **Horberg M**, “Characteristics of Adults with Overweight and Obesity Who Have Not Attempted Weight Loss in the Prior 12 Months,” *Obesity Research & Clinical Practice*, 2020; (5): 449-455.
42. Nassery N, **Horberg MA** (co-lead author), Rubenstein KB, Certa JM, Watson E, Somasundaram B, Shamim E, Townsend JL, Galiatsatos P, Pitts SI, Hassoon A, Newman-Toker DE. Antecedent treat-and-release diagnoses prior to sepsis hospitalization among adult emergency department patients: a look-back analysis employing insurance claims data using Symptom-Disease Pair Analysis of Diagnostic Error (SPADE) methodology. *Diagnosis (Berl)*. 2021 Feb 25. doi: 10.1515/dx-2020-0140. Epub ahead of print. PMID: 33650389.
43. Finch A, Crowell A, Bhatia M, Parameshwarappa P, Chang Y, Martinez J, **Horberg M**, “Exploiting Hierarchy in Medical Concept Embedding,” *JAMIA Open*, 2021 Mar 16;4(1):o0ab022.
44. Finch A, Crowell A, Chang YC, Parameshwarappa P, Martinez J, **Horberg M**, “A Comparison of Attentional Neural Network Architectures for Modeling with Electronic Medical Records,” *JAMIA Open*, 2021; August 12, 4(3): o0ab064.



45. Finch A, Crowell A, Chang YC, Parameshwarappa P, Martinez J, **Horberg M**, "A Comparison of Attentional Neural Network Architectures for Modeling with Electronic Medical Records," *JAMIA Open*, 2021; August 12, 4(3): ooab064.
46. Jonas C, Rubenstein K, Watson E, Basra S, **Horberg M**, "A Comprehensive Coordinator Supported Hepatitis C Virus Testing and Linkage to Treatment Program at Kaiser Permanente Mid-Atlantic States," *Viruses*, 2021; 13(11) 2140.
47. **Horberg M**, Eberhart L, Bhatia M, Jonas C, Cherico-Hsui S, Tamrat Y, Bhandari B, Kadlecik P, Gahunia M, "Patient Demographics and the Utilization of a Novel Three Anatomic Site Testing Panel Including Rectal Self-Collection as Compared to Usual Care Testing," *Sexually Transmitted Diseases*, 2021; e-pub ahead of print
48. **Horberg M**, Watson E, Bhatia M, Jefferson C, Certa J, Kim S, Fathi L, Althoff K, Williams C, Moore R, "Post-Acute Sequelae of SARS-CoV-2: Clinical Conditions Definitions and Comparison in a Matched Cohort," *Nature Communications*, 2022 Oct 12;13(1):5822. doi: 10.1038/s41467-022-33573-6
49. Miller M, Eberhart L, Jefferson C, **Horberg M**, "Beyond Antiretroviral Treatment: Patterns and Factors Associated with Composite Medication Adherence Before and During the COVID-19 Pandemic in Patients with HIV with Multiple Chronic Conditions," *JAIDS*, 2023; 2023 Apr 15;92(5):405-413
50. Jefferson C, Watson E, Certa J, Gordon K, Park L, D'Souza G, Benning L, Abraham A, Agil D, Napravnik S, Sivlerberg M, Leyden W, Skarbinski J, Williams C, Althoff K, **Horberg M**, "Differences in COVID-19 Testing and Adverse Outcomes by Race, Ethnicity, Sex, and Health System Setting in a Large Diverse US Cohort," *PLOS One*, 2022 Nov 23;17(11):e0276742
51. Miller M, Eberhart L, Jefferson C, **Horberg M**, "Beyond Antiretroviral Treatment: Patterns and Factors Associated with Composite Medication Adherence Before and During the COVID-19 Pandemic in Patients with HIV with Multiple Chronic Conditions," *JAIDS*, 2023; 2023 Apr 15;92(5):405-413
52. Burrell T, Kim S, Mohadikar K, Jonas C, Ortiz N, **Horberg M**, "Family Structure and Adolescent Mental Health Service utilization During COVID-19 Pandemic," *Journal Adolescent Health*, 2023; 2023 April 7: S1054-139X(23)00065-4
53. **Horberg M**, Simons S, "Leveraging the Strength of Collaboration in Rapidly Changing Time: The 29<sup>th</sup> Annual Conference of the Health Care Systems Research Network," *Journal of Patient Centered Research Review*, 2023; 18:10 (3): 142-145
54. Ter-Minassian M, Basra S, Watson E, Derus A, **Horberg M**, "Validation of US CDC National Death Index Mortality Data, Focusing on Difference in Race and Ethnicity," *BMJ Health Care Informatics*, 2023; Jul:30 (1) e:100737
55. Burrell T, Sheu Y, Kim s, Mohadikar K, Ortiz N, Jonas C, **Horberg M**, "COVID-19 and Adolescent Outpatient Mental Health Service Utilization," *Academic Pediatrics*, 2023; Jun9:S1876-2859(23)00197-3
56. DeLorenze GN, Follansbee SF, Nguyen DP, Klein DB, **Horberg M**, Quesenberry CP Jr, Blick NT, Tsai AL. Medication error in the care of HIV/AIDS patients: electronic surveillance, confirmation, and adverse events. *Med Care*. 2005 Sep;43(9 Suppl):III63-8.
57. Rhee SY, Fessel WJ, Zolopa AR, Hurley L, Liu T, Taylor J, Nguyen DP, Slome S, Klein D, **Horberg M**, Flamm J, Follansbee S, Schapiro JM, Shafer RW. HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. *J Infect Dis*. 2005 Aug 1;192(3):456-65.

58. Mitsuya Y, Winters MA, Fessel WJ, Rhee SY, Slome S, Flamm J, **Horberg M**, Hurley L, Klein D, Shafer RW. HIV-1 drug resistance genotype results in patients with plasma samples with HIV-1 RNA levels less than 75 copies/mL," *J Acquir Immune Defic Syndr*. 2006 Sep;43(1):56-9.
59. Mitsuya Y, Winters MA, Fessel WJ, Rhee SY, Hurley L, **Horberg M**, Schiffer CA, Zolopa AR, Shafer RW. N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure. *AIDS Res Hum Retroviruses*. 2006 Dec;22(12):1300-5.
60. Gange SJ, Kitahata MM, Saag MS, Bangsberg DR, Bosch RJ, Brooks JT, Calzavara L, Deeks SG, Eron JJ, Gebo KA, Gill MJ, Haas DW, Hogg RS, **Horberg M**, Jacobson LP, Justice AC, Kirk GD, Klein MB, Martin JN, McKaig RG, Rodriguez B, Rourke SB, Sterling TR, Freeman AM, Moore RD. Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). *Int J Epidemiol*. 2007 Apr;36(2):294-301. Epub 2007 Jan 8.
61. Silverberg MJ, Leyden W, **Horberg M**, DeLorenze GN, Klein D, Quesenberry CP Jr. Older age and the response to and tolerability of antiretroviral therapy. *Arch Intern Med*. 2007 Apr 9;167(7):684-91.
62. Cheever LW, Lubinski C, **Horberg M**, Steinberg JL. Ensuring access to treatment for HIV infection. *Clin Infect Dis*. 2007 Dec 15;45 Suppl 4:S266-74.
63. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, Hogg RS, Deeks SG, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, **Horberg M**, Silverberg MJ, Gebo KA, Goedert JJ, Benson CA, Collier AC, Van Rompaey SE, Crane HM, McKaig RG, Lau B, Freeman AM, Moore RD; NA-ACCORD Investigators. Effect of early versus deferred antiretroviral therapy for HIV on survival. *N Engl J Med*. 2009 Apr 30;360(18):1815-26. Epub 2009 Apr 1.
64. Rhee SY, Fessel WJ, Liu TF, Marlowe NM, Rowland CM, Rode RA, Vandamme AM, Van Laethem K, Brun-Vezinet F, Calvez V, Taylor J, Hurley L, **Horberg M**, Shafer RW. Predictive value of HIV-1 genotypic resistance test interpretation algorithms. *J Infect Dis*. 2009 Aug 1;200(3):453-63.
65. Klein DB, Hurley LB, **Horberg M**, Silverberg MJ, Follansbee SE, Flamm JA, Green GM. Increased rates of appendicitis in HIV-infected men: 1991-2005. *J Acquir Immune Defic Syndr*. 2009 Sep 1;52(1):139-40.
66. Silverberg MJ, Chao C, Leyden WA, Xu L, Tang B, **Horberg M**, Klein D, Quesenberry CP Jr, Towner WJ, Abrams DI. HIV infection and the risk of cancers with and without a known infectious cause. *AIDS*. 2009 Nov 13;23(17):2337-45.
67. Deeks SG, Gange SJ, Kitahata MM, Saag MS, Justice AC, Hogg RS, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Benson CA, Collier AC, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, **Horberg M**, Silverberg MJ, Gebo KA, Kushel MB, Goedert JJ, McKaig RG, Moore RD. Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. *Clinical Infectious Diseases*, 2009;49(10):1582-90.
68. Mosen, D, **Horberg M**, Roblin D, Gullion, C, Meenan, R, Leyden, W, Hu, W. Effect of Once-daily FDC Treatment Era on Initiation of cART. *HIV/AIDS-Research and Palliative Care*, 2010 (2): 19-26.
69. Althoff K, Gange S, Klein M, **Horberg M**, Bosch R, Hogg R, Zhang J, Moore R on behalf of NA-ACCORD, "Late Presentation for HIV Care in the United States and Canada," *Clinical Infectious Diseases*, 2010 50(11):1512-1520.

70. Chao C, Xu L, Abrams D, Leyden W, **Horberg M**, Towner W, Klein D, Tang B, Silverberg M, "Survival of Non-Hodgkin Lymphoma Patients with and without HIV-Infection in the Era of Combined Antiretroviral Therapy," *AIDS*, 2010 Jul 17;24(11):1765-70
71. Althoff K, Gebo K, Gange S, Klein M, Brooks J, Hogg R, Bosch R, **Horberg M**, Saag M, Kitahata M, Eron J, Napravnik S, Rourke S, Gill MJ, Rodriguez B, Sterling T, Deeks S, Martin J, Jacobson L, Kirk G, Collier A, Benson C, Silverberg M, Goedert J, McKaig R, Buchacz K, Thorne J, Rachlis A, Moore R, Justice A, for the North American AIDS Cohort Collaboration on Research and Design, "CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation?," *AIDS Research and Therapy*, 2010; 7:45.
72. Breyer B, van den Eeden S, **Horberg M**, Eisenberg M, Deng D, Smith J, Shindel A, "HIV Status is an Independent Risk Factor for Reporting Lower Urinary Tract Symptoms," *Journal of Urology*, 2011; 185(5):1710-5
73. Shindel A, **Horberg M**, Smith J, Breyer B, "Sexual Dysfunction, HIV, and AIDS in Men Who Have Sex with Men," *AIDS, Patient Care, and STDs*, 2011; e-pub ahead of print
74. Chao C, Xu L, Abrams D, Towner W, **Horberg M**, Leyden W, Silverberg M, "HMG-CoA Reductase Inhibitors (Statins) Use and Risk of Non-Hodgkin Lymphoma in HIV+ Persons," *AIDS*, 2011; 25: 1771-1777.
75. Potter M, Somkin C, Ackerson L, Gomez V, Dao T, **Horberg M**, Walsh J, "The FLU-FIT Program at Kaiser Permanente: An effective approach to increase colorectal cancer screening rates," *American Journal of Managed Care*, 2011; 17(8): 577-583
76. Abraham A, Lau B, Deeks S, Moore R, Zhang J, Eron J, Harrigan R, Gill MJ, Kitahata M, Klein M, Napravnik S, Rachalis A, Rodriguez B, Rourke S, Benson C, Bosch R, Collier A, Gebo K, Goedert J, Hogg R, **Horberg M**, Jacobson L, Justice A, Kirk G, Martin J, McKaig R, Silverberg M, Sterling T, Thorne J, Willig J, Gange S, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA, "Missing Data in the Estimation of the Prevalence of Accumulated HIV Drug Resistance in Antiretroviral-Treated Patients in North America," *American Journal of Epidemiology*, 2011; 174(6): 727-735.
77. Sterling T, Lau B, Zhang J, Freeman A, Bosch R, Brooks J, Deeks S, French A, Gange S, Gebo K, Gill MJ, **Horberg M**, Jacobson L, Kirk G, Kitahata M, Klein M, Martin J, Rodriguez B, Silverberg M, Willig J, Eron J, Goedert J, Hogg R, Justice A, McKaig R, Napravnik S, Thorne J, Moore R, for NA-ACCORD of IeDEA, "Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and Canada: Implications for Tuberculosis Screening Strategies," *Journal of Infectious Diseases*, 2011 Sep;204(6):893-901
78. Gallant J, Adimora A, Carmichael JK, **Horberg M**, Kitahata M, Quinlivan EB, Raper J, Selwyn P, Williams S, "Essential Components of Effective HIV Care: A Policy Paper of the HIV Medicine Association of the Infectious Diseases Society of America and the Ryan White Medical Providers Coalition," *Clinical Infectious Diseases*, 2011; 53(11):1043-50
79. Silverberg M, Chao C, Leyden W, Xu L, **Horberg M**, Klein D, Towner W, Dubrow R, Quesenberry C, Neugebauer R, Abrams D, "HIV Infection, Immunodeficiency, Viral Replication, and the Risk of Cancer," *Cancer Epidemiology and Biomarkers Prevention*, 2011 Dec;20(12):2551-9
80. Chao C, Tang B, Towner W, Silverberg M, Hurley L, **Horberg M**, Short Term Clinical Outcomes among Treatment Experienced HIV+ Patients with Early Low Level Viremia," *AIDS Patient Care and STDs*, 2012 May;26(5):253-5
81. Silverberg M, Leyden W, Stewart C, Ralston J, **Horberg M**, Carzasty S, Grothaus L, Catz S, "Change in Adherence to Antiretrovirals After Initial Use of an Electronic Shared Medical Record Among HIV-Infected Individuals," *Clinical Medicine & Research*, 2012; 10(3): 144-145.

82. Althoff K, Buchacz K, Hall HI, Zhang J, Hanna D, Rebeiro P, Gange S, Moore R, Kitahata M, Gebo K, Martin J, Justice A, **Horberg M**, Hogg R, Sterling T, Cescon A, Klein M, Thorne J, Crane H, Mugavero M, Napravnik S, Kirk G, Jacobson L, Brooks J, for the NA-ACCORD of IeDEA, "US Trends in Antiretroviral Therapy Use, HIV RNA Plasma Viral Loads and CD4 T-Lymphocyte Counts among HIV-Infected Persons, 2000-2008," *Annals of Internal Medicine*, 2012; 157:325-335
83. Chao C, Leyden WA, Xu L, **Horberg M**, Klein D, Towner WJ, Quesenberry CP Jr, Abrams DI, Silverberg MJ. "Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons," *AIDS*, 2012; 26(17):2223-31
84. Justice A, Modur S, Tate J, Althoff K, Jacobson L, Gebo K, Kitahata M, **Horberg M**, Brooks J, Buchacz K, Rourke S, Rachlis A, Napravnik S, Eron J, Saag M, Moore R, Kirk G, Bosch R, Rodriguez B, Hogg B, Thorne J, Goeder J, Klein M, Gill M, Deeks S, Sterling T, Anastos K, Gange S for The NA-ACCORD and VACS Project Teams, "Predictive Accuracy of the Veterans Aging Cohort Study (VACS) Index for Mortality with HIV Infection: a North America Cross Cohort Analysis," *JAIDS*, 2012; November 26 e-pub ahead of print; 2013 62(2):149-163.
85. Habel L, Ray GT, Silverberg M, **Horberg M**, Yawn B, Castillo A, Quesenberry C, Li Y, Sadier P, Tran T, "The Epidemiology of Herpes Zoster in Patients with Newly Diagnosed Cancer," *Cancer Epidemiology, Biomarkers & Prevention*, 2012; 22(1); 82–90
86. Rebeiro P, Althoff K, Buchacz K, Gill MJ, **Horberg M**, Krentz H, Moore R, Sterling T, Brooks J, Gebo K, Hogg R, Klein M, Martin J, Mugavero M, Rourke S, Thorne J, Gange S, "Retention among North American HIV-Infected Persons in Clinical Care, 2000-2008," *JAIDS*, 2013; 62 (3): 356–362
87. DeLorenze G, **Horberg M**, Silverberg M, Tsai A-L, Quesenberry C, Baxter R, "Annual Incidence of MRSA Infection among HIV-Infected and non-HIV-infected Patients: 16 Years of Surveillance in a Large Health Plan," *Epidemiology and Infection*, 2013, 141(11):2392-402
88. Hanna D, Buchacz K, Gebo K, Hessol N, **Horberg M**, Jacobson L, Kirk G, Kitahata M, Korthuis PT, Moore R, Napravnik S, Patel P, Silverberg M, Sterling T, Willig J, Lau B, Althoff K, Crane H, Collier A, Thorne J, Gill MJ, Klein M, Martin J, Rodriguez B, Burke S, Gange S, for the NA-ACCORD of IeDEA, "Trends and Disparities in Antiretroviral Therapy Initiation and Virologic Suppression among Newly Treatment-Eligible HIV-Infected Individuals in North America, 2001-2009," *Clinical Infectious Diseases*, 2013; 56(8):1174-82
89. Ralston J, Silverberg M, Grothaus L, Leyden W, Ross T, Stewart C, Carzasty S, **Horberg M**, Catz S, "Use of web-based shared medical records among patients with HIV," *American Journal of Managed Care*, 2013;19(4):e114-24 .
90. Mayer K, Gazzard B, Zuniga J, Amico KR, Anderson J, Azad Y, Cairns G, Dedes N, Duncombe C, Fidler S, Granich R, **Horberg M**, McCormack S, Montaner J, Rees H, Schackman B, Sow P, "Controlling the HIV Epidemic with Antiretrovirals: IAPAC Consensus Statement on Treatment as Prevention and Preexposure Prophylaxis," *Journal of International Association of Providers in AIDS Care*, 2013; 12(3): 208-216.
91. Meenan R, **Horberg M**, Silverberg M, Chun C, Williams A, McBurnie MA, Keast E, Leyden W, Xu L, Vijayadeva V, Antoniskis D, "PS2-20: Developing New Quality Measures for HIV Care Using the Electronic Medical Record," *Clinical Medicine and Research*, 2013: 11(3): 160.
92. Hanna D, Buchacz K, Gebo K, Hessol N, **Horberg M**, Jacobson L, Kirk G, Kitahata M, Korthuis PT, Moore R, Napravnik S, Patel P, Silverberg M, Sterling T, Willig J, Collier A, Samji H, Thorne J, Martin J, Rodriguez B, Stuart E, Gange S, for the NA-ACCORD of IeDEA, "Association Between U.S. State AIDS Drug Assistance Program (ADAP) Features and HIV Antiretroviral Therapy Initiation, 2001-2009," *PLOS ONE*, 2013; 8(11):e78952.

93. Silverberg M, Leyden W, Xu L, **Horberg M**, Chao C, Towner W, Hurley L, Quesenberry C, Klein D, "Immunodeficiency and Risk of Myocardial Infarction among HIV-Positive Individuals with Access to Care," *JAIDS*, 2014; 65(2): 160-166.
94. Tran T, Ray GT, **Horberg M**, Yawn B, Castillo A, Saddier P, Habel L, "Complications of Herpes Zoster in Cancer Patients," *Scandinavian Journal of Infectious Diseases*, 2014; 46(7):528-32
95. Marcus J, Chao C, Leyden W, Xu L, Klein D, **Horberg M**, Towner W, Quesenberry C, Abrams D, Van Den Eeden S, Silverberg M, " Prostate Cancer Incidence and Prostate-Specific Antigen Testing among HIV-Positive and HIV-Negative Men," *JAIDS*, 2014;66(5):495-502
96. DeLorenze G, Tsai A-L, **Horberg M**, Quesenberry C, "Cost of care for HIV-infected patients with co-occurring substance use disorder or psychiatric disease: report from a large, integrated health plan," *AIDS Research and Treatment*, 2014; 2014:570546
97. Marcus J, Leyden W, Chao C, Chow F, **Horberg M**, Hurley L, Klein D, Quesenberry C, Towner W, Silverberg M, "HIV Infection and Incidence of Ischemic Stroke," *AIDS*, 2014; 28(13):1911-9
98. Abraham A, Althoff K, Jing Y, Estrella M, Kitahata M, Wester W, Bosch R, Crane H, Eron J, Gill MJ, **Horberg M**, Justice A, Klein M, Krishnasami Z, Mayor A, Moore R, Palella F, Parikh C, Silverberg MJ, Golub E, Jacobson L, McKaig R, Napravnik S, Rodriguez B, and Lucas G for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA), "End Stage Renal Disease Among HIV-Infected Adults in North America," *Clinical Infectious Diseases*, 2015; 60(6):941-9
99. Rebeiro P, **Horberg M**, Gange S, Gebo K, Yehia B, Brooks J, Buchacz K, Silverberg M, Gill J, Moore R, Althoff K, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Strong agreement of Nationally Recommended Retention Measures from the Institute of Medicine and the Department of Health and Human Services: a Cross-Sectional Study," *PLOS ONE*, 2014; Nov 6;9(11):e111772
100. Marcus J, Leyden W, Chao C, Xu L, Quesenberry C, Tien P, Klein D, Towner W, **Horberg M**, Silverberg M, "Differences in Response to Antiretroviral Therapy by Sex and Hepatitis C Infection Status," *AIDS, Patient Care and STDs*, 2015; July 2015, 29(7): 370-378.
101. Marcus JL, Chao C, Leyden W, Xu L, Yu J, **Horberg M**, Klein D, Towner W, Quesenberry C, Abrams D, Silverberg M, "Survival Among HIV-Positive and HIV-Negative Individuals with Common Non-AIDS-Defining Cancers," *Cancer Epidemiol Biomarkers Prev.*, 2015; e-pub ahead of print
102. Maeda J, Bradley J, Eissler S, LoBrano M, Rubin M, Gay M, **Horberg M**, Loftus B, "Expanding Access to Care and Improving Quality in the Mid-Atlantic Safety Net Clinics: Kaiser Permanente's Community Ambassador Program," *The Permanente Journal*, 2015; Spring;19(2):22-7
103. Klein D, Leyden W, Xu L, Chao C, **Horberg M**, Towner W, Hurley L, Marcus J, Quesenberry C, Silverberg, M "Declining Relative Risk for Myocardial Infarction among HIV-Positive Compared with HIV-Negative Individuals with Access to Care," *Clinical Infectious Diseases*, 2015; Apr 15;60(8):1278-80
104. Saberi P, Catz S, Leyden W, Stewart C, Ralston J, **Horberg M**, Grothaus L, Silverberg, M, "Antiretroviral Therapy Adherence and Use of an Electronic Shared Medical Record among People Living with HIV," *AIDS and Behavior*, 2015; e-pub ahead of print
105. Yehia B, Rebeiro P, Althoff K, Agwu A, **Horberg M**, Samji H, Napravnik S, Mayer K, Buchacz K, Tedaldi E, Silverberg M, Thorne J, Burchell A, Rourke S, Rachlis A, Mayor A, Gill M, Zinski A, Ohl M, Anastos K, Abraham A, Moore R, Gange S, Gebo K for the North American AIDS Cohort Collaboration

on Research and Design (NA-ACCORD), "The Impact of Age on Retention in Care and Viral Suppression," *JAIDS*, 2015 Apr 1;68(4):413-9

106. Silverberg M, Lau B, Achenbach C, Jing Y, Althoff K, D'Souza G, Engels E, Hessel N, Brooks J, Burchell A, Gill MJ, Goeder J, Hogg R, **Horberg M**, Kirk G, Kitahata M, Korhuis P, Mathews W, Mayor A, Modur S, Napravnik S, Novak R, Patel P, Rachlis A, Sterling T, Willig J, Justice A, Moore R, Dubrow R for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Cumulative Incidence of Cancer among HIV-infected Individuals in North America," *Annals of Internal Medicine*, 2015; 163(7):507-518.
107. Koethe J, Jenkins C, Lau B, Shepherd B, Justice A, Tate J, Buchacz K, Napravnik S, Mayor A, **Horberg M**, Blashill A, Willig A, Wester CW, Gill MJ, Thorne JE, Klein M, Eron J, Moore R, Sterling T for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Rising Obesity Prevalence and Weight Gain among Adults Starting Antiretroviral Therapy in the United States and Canada, 1998 to 2010," *AIDS Res Hum Retroviruses*, 2015 Sep 9; e-pub ahead of print
108. Marcus JL, Neugebauer R, Leyden W, Chao C, Xu L, Quesenberry C, Klein D, Towner W, **Horberg M**, Silverberg M, "Use of abacavir and risk of cardiovascular disease among HIV-infected individuals", *JAIDS*, 2015; e-pub ahead of print
109. Gold R, Hollombe C, Bunce A, Nelson C, Davis JV, Cowburn S, Perrin N, DeVoe J, Mossman N, Boles B, **Horberg M**, Dearing J, Jaworski V, Cohen D, Smith D, "Study Protocol for "Study of Practices Enabling Implementation and Adaptation in the Safety Net (SPREAD-NET)": A Pragmatic Trial Comparing Implementation Strategies," *Implementation Science*, 2015; 10(1): 144-152.
110. Rebeiro P, Althoff K, Lau B, Gill MJ, Abraham A, **Horberg M**, Kitahata M, Yehia B, Samji H, Brooks J, Buchacz K, Napravnik S, Silverberg M, Rachlis A, Gebo K, Sterling T, Moore R, Gange S, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Laboratory Measures as Proxies for Primary Care Encounters: Implications for Quantifying Clinical Retention among HIV-Infected Adults in North America, *American Journal of Epidemiology*, 2015; Dec 1;182(11):952-60
111. Althoff K, Rebeiro P, Hanna D, Padgett D, **Horberg M**, Grinsztejn B, Abraham A, Hogg R, Gill MJ, Wolff M, Mayor A, Rachlis A, Williams C, Sterling T, Kitahata M, Buchacz K, Thorne J, Cesar C, Cordero F, Rourke S, Madero J, Pape J, Cahn P, McGowan C, "A picture is worth a thousand words: Maps of HIV indicators to inform research, programs, and policy, from NA-ACCORD and CCASAnet clinical cohorts," *Journal of the International AIDS Society*, 2016 Apr 4;19(1):20707.
112. Marcus J, Chao C, Leyden W, Xu L, Quesenberry C, Klein D, Towner W, **Horberg M**, Silverberg M, "Narrowing the Gap in Life Expectancy Between HIV-Infected and HIV-Uninfected Individuals with Access to Care: A Cohort Study," *JAIDS*, 2016; e-pub ahead of print
113. Gold R, Esterberg E, Hollombe C, Arkind J, Vakarcz PA, Tran H, Burdick T, Devoe JE, **Horberg M**, "Low Back Imaging When not Indicated: A Descriptive Cross-System Analysis," *Permanente Medical Journal*, 2016 Spring;20(2):25-33
114. Rebeiro P, Gange S, **Horberg M**, Abraham A, Napravnik S, Samji H, Yehia B, Althoff K, Moore R, Kitahata M, Sterling T, Curriero F, "Geographic Variations in Retention in Care among HIV-Infected Adults in the United States," *PLOS ONE*, 2016; Jan 11;11(1):e0146119
115. Paolino A, McGlynn E, Lieu T, Nelson A, Prausnitz S, **Horberg M**, Arterburn D, Gould M, Laws R, Steiner R, "Building a Governance Strategy for CER: The Patient Outcomes Research to Advance Learning (PORTAL) Network Experience," *EGEMS*, 2016 Mar 28;4(2):1216
116. Koethe J, Jenkins C, Lau B, Shepherd B, Wester W, Rebeiro P, Silverberg M, Thorne J, Gill J, Mayor A, Willig A, Bosch R, **Horberg M**, Justice A, Sterling T, Moore R, "Higher Time-Updated Body

Mass Index: Association with Improved CD4+ Cell Recovery of HIV Treatment,” *JAIDS*, 2016; 73 (2): 197-204

117. Wong C, Gange S, Buchacz K, Moore RD, Justice A, **Horberg M**, Gill MJ, Koethe J, Rebeiro P, Silverberg M, Palella F, Patel P, Kitahata M, Crane H, Abraham A, Samji H, Napravnik S, Ahmed T, Thorne J, Bosch R, Mayor A, Althoff K, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), “First Occurrence of Diabetes, Chronic Kidney Disease, and Hypertension among North American HIV-Infected Adults, 2000-2013,” *Clinical Infectious Diseases*, 2017; 64(4): 459-467.
118. Koebnick C, Fischer H, Daley M, Ferrara A, **Horberg M**, Waitzfelder B, Young D, Gould M, “Interacting effects of obesity, race, ethnicity and sex on the incidence and control of adult-onset asthma,” *Allergy, Asthma & Clinical Immunology*, 2016; 12:50.
119. Marcus J, Baxter R, Leyden W, Muthulingam D, Yee A, **Horberg M**, Klein D, Towner W, Chao C, Quessenberry C, Silverberg M, “Invasive Pneumococcal Disease among HIV-Infected and HIV-Uninfected Adults in a Large Integrated Healthcare System,” *AIDS, Patient Care, and STDs*, 2016; 30 (10): 463-470
120. Young D, Waitzfelder B, Arteburn D, Nichols G, Ferrara A, Koebnick C, Yamamoto A, Daley M, Bessesen D, Sherwood N, **Horberg M**, Lewis K, “Cohort Profile: The Patient Outcomes Research to Advance Learning (PORTAL) Network Adult Overweight/Obesity Cohort: Its Development and Description,” *JMIR Research Protocols*, 2016; 5(2): e87.
121. Dubrow R, Qin L, Lin H, Hernández-Ramírez RU, Neugebauer RS, Leyden W, Althoff KN, Achenbach CJ, Hessel NA, Modur SP, D’Souza G, Bosch RJ, Grover S, **Horberg M**, Kitahata MM, Mayor AM, Novak RM, Rabkin CS, Sterling TR, Goedert JJ, Justice AC, Engels EA, Moore RD, Silverberg MJ, “Associations of CD4+ T-cell count, HIV-1 RNA viral load, and antiretroviral therapy with Kaposi sarcoma risk among HIV-infected persons in the United States and Canada,” *JAIDS*, 2017 Apr 7. [Epub ahead of print]
122. Rebeiro P, Abraham A, **Horberg M**, Althoff K, Yehia B, Buchacz K, Lau B, Sterling T, Gange S, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), “Sex, Race, and HIV Risk Disparities in Discontinuity of HIV Care after Antiretroviral Therapy Initiation in the United States and Canada,” *AIDS, Patient Care, and STDs*, 2017 Mar; 31(3):129-144.
123. Muzaale A, Althoff K, Sperati CJ, Abraham A, Kucirka L, Massie A, Kitahata M, **Horberg M**, Justice A, Fischer M, Silverberg M, Butt A, Boswell S, Rachlis A, Mayor A, Gill MJ, Eron J, Napravnik S, Dorzd D, Martin J, Bosch R, Durand C, Locke J, Moore R, Lucas G, Segev D, “Risk of End Stage Renal Disease in HIV-Positive Potential Live Kidney Donors,” *American Journal of Transplantation*, 2017; 17(7): 1823-1832
124. Gonsalves G, Paltiel A, Cleary P, Gill MJ, Kitahata M, Rebeiro P, Silverberg MJ, **Horberg M**, Hall HI, Abraham A, Kaplan E, “A Flow Based Model of the HIV Care Continuum in the United States,” *JAIDS*, 2017; 75(5): 548-553.
125. Kanwal F, Bacon B, Beste L, Brill J, Gifford A, Gordon S, **Horberg M**, Manthey J, Reau N, Rustgi V, Younossi Z, “Hepatitis C Virus Infection Care Pathway-A Report from the American Gastroenterological Association Institute HCV Care Pathway Work Group,” *Gastroenterology*, 2017; 152(6): 1588-1598.
126. Chen R, Scherzer R, Hsue P, Jotwani V, Estrella M, **Horberg M**, Grunfeld C, Shlipak M, “Association of Tenofovir Use with Risk of Incident Heart Failure in HIV-infected Patients: A Retrospective Cohort Study,” *Journal of the American Heart Association*, 2017; 6(4): pii: e005387.

127. Nichols G, **Horberg M**, Koebnick C, Young D, Waitzfelder B, Sherwood N, Daley M, Ferrara A, “Cardiometabolic Risk Factors Among 1.3 Million Individuals Without Diabetes Affected by Overweight or Obesity,” *Preventing Chronic Disease*, 2017; 14: E22
128. Marcus J, Leyden W, Chao C, **Horberg M**, Klein D, Quesenberry C, Towner W, Silverberg M, “Immunodeficiency, AIDS-Related Pneumonia, and Risk of Lung Cancer among HIV-Infected Individuals,” *AIDS*, 2017; 31(7): 989-993.
129. Wong C, Gange S, Buchacz K, Moore R, Justice A, **Horberg M**, Gill M, Koethe J, Rebeiro P, Silverberg M, Palella F, Patel P, Kitahata M, Crane H, Abraham A, Samji H, Napravnik S, Ahmed T, Thorne J, Bosch R, Mayor A, Althoff K, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), “First Occurrence of Diabetes, Chronic Kidney Disease, and Hypertension among North American HIV-Infected Adults, 2000-2013,” *Clinical Infectious Diseases*, 2017; 64(4): 459-467.
130. Wong C, Gange S, Moore R, Justice A, Buchacz K, Abraham A, Rebeiro P, Koethe J, Martin J, **Horberg M**, Boyd C, Kitahata M, Crane H, Gebo K, Gill MJ, Silverberg M, Palella F, Patel P, Samji H, Thorne J, Rabkin C, Mayor A, Althoff K, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), “Multimorbidity among Individuals Living with HIV in the US,” *Clinical Infectious Diseases*, 2018; 66(8): 1230-1238.
131. Chi F, Green C, Hinman A, Mertens J, Beck A, **Horberg M**, Weisner C, Campbell C, “Patient and System Characteristics Associated with performance on the HEDIS Measures of Alcohol and Other Drug Treatment Initiation and Engagement,” *Journal of Addiction Medicine*, 2018; e-pub ahead of print
132. Silverberg M, Leyden W, Leibowitz A, Hare C, Jang H, Sterling S, Catz S, Parthasarathy S, **Horberg M**, Satre D, “Factors Associated with Hazardous Alcohol Use and Motivation to Reduce Drinking among HIV Primary Care Patients: Baseline Findings from the Health & Motivation Study,” *Addictive Behaviors*, 2018; 84: 110-117.
133. Yarborough B, Chi F, Green C, Hinman A, Mertens J, Beck A, **Horberg M**, Weisner C, Campbell C, “Patient and System Characteristics Associated with performance on the HEDIS Measures of Alcohol and Other Drug Treatment Initiation and Engagement,” *Journal of Addiction Medicine*, 2018; March 19; e-pub ahead of print
134. Young D, Fischer H, Arterburn D, Bessesen D, Cromwell L, Daley M, Desair J, Ferrara A, Fitzpatrick S, **Horberg M**, Koebnick C, Nau C, Oshiro C, Waitzfelder B, Yamamoto A, “Associations of Overweight/Obesity and Socioeconomic Status with Hypertension Prevalence Across Racial and Ethnic Groups,” *The Journal of Clinical Hypertension*, 2018; 20(3): 532-540.
135. Altekruze S, Shiels M, Modur S, Land S, Crothers K, Kitahata M, Thorne J, Mathews W, Fernandez-Santos D, Mayor A, Gill J, **Horberg M**, Brooks J, Moore R, Silverberg M, Althoff K, Engels E, “Cancer Burden Attributable to Cigarette Smoking among HIV-Infected People in North America,” *AIDS*, 2018; 32(4): 513-521.
136. Elion RA, Althoff KN, Zhang J, Moore RD, Gange SJ, Kitahata MM, Crane HM, Drozd DR, Stein JH, Klein MB, Eron JJ, Silverberg MJ, Mathews WC, Justice AC, Sterling TR, Rabkin CS, Mayor AM, Klein DB, **Horberg M**, Bosch RJ, Eyawo O, Palella FJ Jr; North American AIDS Cohort Collaboration on Research and Design of IeDEA, “Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions among Adults with HIV,” *JAIDS*, 2018; 78(1): 62-72.
137. Bradley H, Althoff K, Buchacz K, Boswell S, Brooks J, Gill MJ, **Horberg M**, Kitahata M, Marconi V, Mayor A, Moore R, Mugavero M, Napravnik S, Paz-Bailey G, Prejean J, Rebeiro P, Rentsch C, Shouse RL, Sullivan P, Thorne J, Yehia B, Rosenberg E, “Viral Suppression among Persons in HIV Care during 2009-2013: Sampling Bias in Medical Monitoring Project (MMP) Surveillance Estimates,”



138. Eby J, Lane M, **Horberg M**, Gentry C, Coffin S, Ray A, Sheridan K, Bratzler D, Wheeler D, Sarumi M, Barlam T, Kim T, Rodriguez A, Nahass R, "How Do You Measure Up: Quality Measurement for Improving Patient Care and Establishing the Value of Infectious Diseases Specialists," *Clinical Infectious Diseases*, 2018; (e-Pub ahead of print)
139. Tartof S, Hsu J-W, Wei R, Rubenstein K, Hu H, Arduino JM, **Horberg M**, Derose S, Qian L, Rodriguez C, "Kidney Function Decline in Patients with Chronic Kidney Disease and Untreated Hepatitis C Infection," *Clinical Journal of the American Society of Nephrology*, 2018; 13(10): 1471-1478.
140. Grover S, Desir F, Jing Y, Bhatia RK, Trifiletti D, Swisher-McClure S, Kobie J, Moore R, Rabkin C, Silverberg M, Salters K, Mathews W, Gill MJ, Thorne JE, Castilho J, Kitahata M, **Horberg M**, Achenbach C, Mayor A, Althoff K, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Reduced Cancer Survival Among Adults with HIV and AIDS-Defining Illnesses Despite No Difference in Cancer Stage at Diagnosis," *Journal AIDS*, 2018; 79(4): 421-429.
141. Desir F, Lesko C, Moore R, **Horberg M**, Wong C, Crane H, Silverberg M, Thorne J, Rachlis B, Rabkin C, Mayor A, Mathews W, Althoff K, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "One Size Fits (n)One: The Influence of Sex, Age, and Sexual Human Immunodeficiency Virus (HIV) Acquisition Risk on Racial/Ethnic Disparities in the HIV Care Continuum in the United States," *Clinical Infectious Diseases*, 2018; (e-Pub ahead of print)
142. Yanik E, Hernandez-Ramirez R, Qin L, Lin H, Leyden W, Neugebauer R, **Horberg M**, Moore R, Mathews W, Justice A, Hessol N, Mayor A, Gill M, Brooks J, Sun J, Althoff K, Engels E, Silverberg M, Dubrow R, "Brief Report: Cutaneous Melanoma Risk among People with HIV in the United States and Canada," *Journal AIDS*, 2018; 78(5): 499-504.
143. Hechter R, **Horberg M**, Weisner C, Campbell C, Contreras R, Chen L, Yarborough JH, Lapham G, Haller I, Ahmedani B, Binswanger I, Kline-Simon A, Satre D, "Healthcare Effectiveness Data and Information Set (HEDIS) Measures of Alcohol and Drug Treatment Initiation and Engagement among People Living with Human Immunodeficiency Virus (HIV) and Patients without an HIV Diagnosis," *Substance Abuse*, 2019; (e-pub ahead of print)
144. Lewis KH, Fischer H, Ard J, Barton L, Bessesen D, Daley M, Desai J, Fitzpatrick S, **Horberg M**, Koebnick C, Oshiro C, Yamamoto A, Young D, Arterburn D, "Safety and Effectiveness of Long-Term Phentermine Use: Clinical Outcomes and Electronic Health Record Cohort," *Obesity (Silver Spring)*, 2019; 27(4): 591-602.
145. Althoff K, Gebo K, Moore R, Boyd C, Justice A, Wong C, Lucas G, Klein M, Kitahata M, Crane H, Silverberg M, Gill MJ, Mathews W, DuBrow R, **Horberg M**, Rabkin C, Klein D, Lo Re V, Sterling T, Desir F, Gange S, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the US and Canada: a Collaboration of Cohort Studies," *Lancet HIV*, 2019; 6(2) e93-e104.
146. Poteat T, Hanna DB, Rebeiro PF, Klein M, Silverberg MJ, Eron JJ, **Horberg M**, Kitahata MM, Mathews WC, Mattocks K, Mayor A, Rich AJ, Reisner S, Thorne J, Moore RD, Jing Y, Althoff KN; North American AIDS Cohort Collaboration On Research and Design of the International Epidemiology Databases to Evaluate AIDS, "Characterizing the Human Immunodeficiency Virus Care Continuum Among Transgender Women and Cisgender Women and Men in Clinical Care: A Retrospective Time-series Analysis," *Clinical Infectious Disease*, 2019, (e-pub ahead of print)
147. Zhu Y, Sidell M, Arterburn D, Daley M, Desai J, Fitzpatrick S, **Horberg M**, Koebnick C, McCormick E, Oshiro C, Young D, Ferrara A, "Racial/Ethnic Disparities in the Prevalence of Diabetes and Prediabetes by Body Mass Index: Patient Outcomes Research to Advance Learning (PORTAL) Multi-Site Cohort of Adults in the US," *Diabetes Care*, 2019 (e-pub ahead of print)

148. Satre D, McNeely J, Hare B, Leibowitz A, Volberding P, Weisner C, Silverberg M, Sally S, Anderson A, **Horberg M**, Levine-Hall T, Flamm J, “Implementing Electronic Substance Use Disorder and Depression and Anxiety Screening and Behavioral Interventions in Primary Care Clinics Serving People with HIV: Protocol for Promoting Access to Care Engagement (PACE) Trial,” *Contemporary Clinical Trials*, 2019; Sep;84:105833
149. Levy M, Monroe A, **Horberg M**, Benator D, Molock S, Doshi R, Powers-Happ L, Castel A, on behalf of the DC Cohort Executive Committee, “Pharmacologic Treatment of Psychiatric Disorders and Time with Unsuppressed HIV Viral Load in a Clinical HIV Cohort,” *JAIDS*, 2019. (e-pub ahead of print)
150. Satre DD, Leibowitz AS, Leyden W, Catz SL, Hare CB, Jang H, Lam JO, Bryant KJ, Weisner CM, Sterling SA, **Horberg M**, Volberding P, Silverberg MJ, “Interventions to Reduce Unhealthy Alcohol Use among Primary Care Patients with HIV: the Health and Motivation Randomized Clinical Trial,” *Journal of General Internal Medicine*, 2019; (e-pub ahead of print)
151. Lo Re V 3rd, Newcomb CW, Carbonari DM, Roy JA, Althoff KN, Kitahata MM, Reddy KR, Lim JK, Silverberg MJ, Mayor AM, **Horberg M**, Cachay ER, Kirk GD, Hull M, Gill J, Sterling TR, Kostman JR, Peters MG, Moore RD, Klein MB, Kim HN; North American AIDS Cohort Collaboration on Research and Design of IeDEA, “Determinants of Liver Complications Among HIV/Hepatitis B Virus-Coinfected Patients,” *JAIDS*, 2019; Sep 1;82(1):71-8
152. Hernández-Ramírez RU, Qin L, Lin H, Leyden W, Neugebauer RS, Althoff KN, Hessel NA, Achenbach CJ, Brooks JT, Gill MJ, Grover S, **Horberg M**, Li J, Mathews WC, Mayor AM, Patel P, Rabkin CS, Rachlis A, Justice AC, Moore RD, Engels EA, Silverberg MJ, Dubrow R; North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS, “Association of immunosuppression and HIV viremia with anal cancer risk in persons living with HIV in the United States and Canada,” *Clinical Infectious Disease*, 2019 (e-pub ahead of print)
153. Althoff K, Wong C, Hogan B, Desir F, You B, Humes E, Zhang J, Jing Y, Modur S, Lee J, Freeman A, Kitahata M, van Rompey S, Mathews WC, **Horberg M**, Silverberg M, Mayor A, Salters K, Moore R, Gange S for the North American AIDS Cohort Collaboration on Research and Design, “Mind the Gap: Observation Windows to Define Periods of Event Ascertainment in Longitudinal Electronic Medical Record Data,” *Annals of Epidemiology*, 2019; 33:54-63
154. Levy M, Monroe A, **Horberg M**, Benator D, Castel D, on behalf of the DC Cohort Executive Committee, “Is Low-Level Viraemia Associated with Serum Lipid Profiles among HIV Controllers?,” *HIV Medicine*, 2020; 21, e14-e16
155. Lam J, Levine-Hall T, Hood N, Alexeeff S, **Horberg M**, Young-Wolff K, Sterling S, Williams A, Weisner C, Satre D, Silverberg M, “Smoking and Cessation Treatment among Persons with and without HIV in an Integrated Health System,” *Drug and Alcohol Dependence*, 2020; 18:213:108128.
156. Happ L, Monroe A, Young H, Ma Y, Greenberg A, **Horberg M**, Castel A, “Individual- and Clinical-Level Factors Associated with Achieving Glycemic Control in a Large Cohort of People with HIV in Care—Washington, DC,” *JAIDS*, 2020; 85 (1): 113-122.
157. Marcus J, Leyden W, Alexeeff S, Anderson A, Hechter R, Hu H, Lam J, Towner W, Yuan Q, Silverberg M, **Horberg M**, “Comparison of Life Expectancy and Comorbidity-Free Life Expectancy of Insured Adults With and Without HIV, 2000-2016,” *JAMA Open*, 2020; 3(6): e207954.
158. Fitzpatrick S, Rosales A, Brown S, Arterburn D, Daley M, **Horberg M**, Koebnick C, Oshiro C, Young D, “Behavioral and Psychological Factors Associated with 5-Year weight Trajectories within the PORTAL Overweight/Obesity Cohort,” *Obesity Science and Practice*, 2020; 6(3): 272-281.

159. Spence A, Levy M, Monroe A, Castel A, Timpone J, **Horberg M**, Adams-Campbell L, Kumar P, “Cancer Incidence and Cancer Screening Practices among a Cohort of Persons Receiving HIV Care in Washington, DC,” *Journal of Community Health*, 2021; 46: 75-85.
160. Bourgi K, Jenkins C, Rebeiro P, Palella F, Moore R, Althoff K, Gill MJ, Rabkin C, Gange S, **Horberg M**, Margolick J, Li J, Wong C, Willig A, Lima V, Crane H, Thorne J, Silverberg MK, Kirk G, Mathews WC, Sterling T, Lake J, “Weight Gain among Treatment-Naïve Persons with HIV Starting Integrase Inhibitors in a Large Observational Cohort in the United States and Canada,” *Journal of the International AIDS Society*, 2020; 23(4): e25484.
161. Opoku J, Doshi R, Castel A, Sorensen I, **Horberg M**, Allston A, Kharfen M, Greenber A, “Comparison of Clinical Outcomes of Persons Living with HIV by Enrollment Status in Washington, DC: Evaluation of a Large Longitudinal HIV Cohort Study,” *JMIR Public Health Surveillance*, 2020; 6(2): e16061.
162. Roriguez-Watson C, Rubenstein K, Jonas MC, Sun Y, **Horberg M**, Loftus B, “Hepatitis C Care Pathway Associated with Increased Screening, Confirmation, and Diagnosis Communication to Patients,” *Clinical Gastroenterology and Hepatology*, 2021 Mar;19(3):607-609.
163. Secco A, Akselrod H, Czeresnia J, Levy M, Byrne M, Monroe A, Lucar J, **Horberg M**, Castel A, Doshi R, Rivasplata H, Squires L, Parenti D, Benator D, on behalf of the DC Cohort Executive Committee, “Sexually Transmitted Infections in Person Living with HIV Infection and Estimated HIV Transmission Risk; Trends over Time from the DC Cohort,” *Sexually Transmitted Infections*, 2020; 96(2): 89-95.
164. Gold R, Bunce A, Cowburn S, Davis J, Nelson J, Nelson C, Hicks E, Cohen D, **Horberg M**, Melgar G, Dearing J, Seabrook J, Mossman N, Blukley J, “Does Increased Implementation Support Improve Community Clinics’ Guidelines-Concordant Care? Results of a Mixed Methods, Pragmatic Comparative Effectiveness Trial,” *Implementation Science*, 2019, 14(1): 100.
165. Satre D, Sarovar V, Leyden W, Hare CB, Catz S, Bryant K, Williams E, Hojilla JC, **Horberg M**, Silverberg M, “Change in Days of Unhealthy Alcohol Use and Antiretroviral Therapy Adherence, HIV RNA Levels, and Condomless Sex: A Secondary Analysis of Clinical Trial Data,” *AIDS and Behavior*, 2020; 24(6): 1784-1792.
166. Monroe A, Happ L, Rayeed N, Ma Y, Jaurretche M, Terzian A, Trac K, **Horberg M**, Greenberg A, Castel A, on behalf of the DC Cohort Executive Committee, “Clinic-Level Factors Associated with Time to Antiretroviral Initiation and Viral Suppression in a Large Urban Cohort,” *Clinical Infectious Diseases*, 2019; e-pub ahead of print.
167. Saxon D, Iwamoto S, Mettenbrink C, McCormick E, Arterburn D, Daley M, Oshiro C, Koebnick C, **Horberg M**, Young D, Bessesen D, “Antiobesity Medication Use in 2.2 Million Adults Across Eight Large Health Care Organizations: 2009-2015,” *Obesity (Silver Spring)*, 2019; 27(12): 1975-1981.
168. Althoff K, Chandran A, Zhang J, Miranda W, Gange S, Sterling T, Gill MJ, Justice A, Palella F, Rebeiro P, Silverberg M, Mayor A, **Horberg M**, Thorne J, Rabkin C, Mathews WC, Klein M, Humes E, Lee J, Hogg R, Moore R, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), “Life-Expectancy Disparities Among Adults with HIV in the United States and Canada: The Impact of a Reduction in Drug- and Alcohol-Related Deaths Using the Lives Saved Simulation Model,” *American Journal of Epidemiology*, 2019; 188(12): 2097-2109
169. Satre D, Parthasarathy S, Silverberg M, **Horberg M**, Young-Wolff K, Willisams E, Volberding P, Campbell C, “Health Care Utilization and HIV Clinical Outcomes among Newly Enrolled Patients Following Affordable Care Act Implementation in A California Integrated Health System: A Longitudinal Study,” *BMC Health Services Research*, 2020; 20 (1): 1030-1042.

170. Davy-Mendez T, Napravnik S, Hogan B, Althoff K, Gebo K, Moore R, **Horberg M**, Silverberg M, Gill MJ, Crane H, Marconi V, Bosch R, Colasanti J, Sterling T, Mathews W, Mayor A, Nanditha N, Buchacz K, Li J, Rebeiro P, Thorne J, Nijhawan A, Van Duin D, Wohl D, Eron J, Berry S for the North American AIDS Cohort Collaboration on Research and Design, "Hospitalization Rates and Causes among Persons with HIV in the US and Canada," *Journal of Infectious Diseases*, 2020; October 21, online ahead of print.
171. Silverberg M, Hood N, Levine-Hall T, Anderson A, Alexeeff S, Lam J, Slome S, Flamm J, Hare C, Ross T, Justice A, Sterne J, Williams A, Bryant K, Weisner C, **Horberg M**, Sterling S, Satre D, "Helath System-Based Unhealthy Alcohol Use Screening and Trement Comparing Demographically-Matched Participants With and Without HIV," *Alcoholism Clinical and Experimental Research*, 2020; October 17, online ahead of print.
172. Rebeiro P, Jenkins C, Bian A, Lake J, Bourgi K, Moore R, **Horberg M**, Matthews W, Silverberg M, Thorne J, Mayor A, Lima V, Palella F, Saag M, Althoff K, Gill MJ, Wong C, Klein M, Crane H, Marconi V, Shepherd B, Sterling T, Koethe J, "Risk of Incident Diabetes Mellitus, Weight Gain, and their Relationships with Integrase Inhibitor-Based Initial Antiretroviral Therapy among Persons with HIV in the US and Canada," *Clinical Infectious Diseases*, 2020; Sept 16, online ahead of print.
173. Wallace D, **Horberg M**, Benator D, Greenberg A, Castel A, Monroe A, Powers-Happ L, "Diabetes Mellitus Control in a Large Cohort of HIV-infected People in Care-Washington, DC," *AIDS Care*, 2020; August 18, online ahead of print
174. Silverberg M, Leyden W, Hernandez-Ramirez R, Qin L, Lin H, Justice A, Hessol N, Achenbach C, D'Souza Gypsay A, Engels E, Althoff K, Mayor A, Sterling T, Kitahata M, Bosch R, Saag M, Rabkin C, **Horberg M**, Gill MJ, Grover S, Mathews C, Li J, Crane H, Gange S, Lau B, Moore R, Dubrow R, Neugebauer R, for the North American AIDS cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS, "Timing of Antiretroviral Therapy Initiation and Risk of Cancer among Person with HIV," *Clinical Infectious Diseases*, 2020; August 12, online ahead of print
175. Lu H, Cole S, Westreich D, Hudgens M, Adimora A, Althoff K, Silverberg M, Buchacz K, Li J, Edwards J, Rebeiro P, Lima V, Marconi V, Sterling T, **Horberg M**, Gill MJ, Kitahata M, Eron J, Moore R, for the North American AIDS cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS, "Clinical Effectiveness of Integrase Strand Transfer Inhibitor-Based Antiretroviral Regimens among Adults with Human Immunodeficiency Virus: A Collaboration of Cohort Studies in the United States and Canada," *Clinical Infectious Diseases*, 2020 August 11, online ahead of print
176. Doshi R, Byrne M, Levy M, Varga L, Kuo I, **Horberg M**, Castel A, Monroe A, on behalf of the DC Cohort Executive Committee, "Association of Substance Use Disorders with Mortality and Engagement in Care among a Clinical Cohort of People with HIV in Washington, DC," *AIDS and Behavior*, 2021; e-pub ahead of print
177. Watanabe J, Simon G, **Horberg M**, Platt R, Hernandez A, Califf R, "When are Treatment Blinding and Treatment Standardization Necessary in Real-World Clinical Trials?," *Clinical Pharmacology & Therapeutics*, 2021; e-ppub ahead of print
178. Franklin J, Platt R, Dreyer N, London A, Simon G, Watanabe J, **Horberg M**, Hernandez A, Califf R, "When Can Nonrandomized Studies Support Valid Inference Regarding Effectiveness or Safety of New Medical Treatments?," *Clinical Pharmacology & Therapeutics*, 2021; e-pub ahead of print
179. Davy-Mendez T, Napravnik S, Eron J, Cole S, Van Duin D, Wohl D, Gebo K, Moore R, Althoff K, Poteat T, Gill MJ, **Horberg M**, Silverberg M, Nanditha N, Thorne J, Berry S, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA, "Racial, Ethnic, and

Gender Disparities in Hospitalizations among Persons with HIV in the United States and Canada, 2005-2015," *AIDS*, 2021; e-pub ahead of print

180. Miller M, Watson E, **Horberg M**, Bhatia M, McCarthy R., "Patient Experience after Modifying Visit Delivery During the COVID-19 Pandemic," *AJMC*, 2021 Feb 1;27(2):e54-e63
181. Lee J, Humes E, Hogan B, Buchacz K, Eron J, Gill MJ, Sterling T, Rebeiro P, Dias Lima V, Mayor A, Silverberg M, **Horberg M**, Moore R, Althoff K, for the North American AIDS cohort Collaboration on Research and Design, "CD4 Count at Entry into HIV Care and at Antiretroviral Therapy Prescription in the US, 2005-2018," *Clinical Infectious Diseases*, 2020; e-pub ahead of print
182. Sun J, Althoff KN, Jing Y, **Horberg MA**, Buchacz K, Gill MJ, Justice AC, Rabkin CS, Goedert JJ, Sigel K, Cachay E, Park L, Lim JK, Kim HN, Lo Re V 3rd, Moore R, Sterling T, Peters MG, Achenbach CJ, Silverberg M, Thorne JE, Mayor AM, Crane HM, Kitahata MM, Klein M, Kirk GD; North American AIDS Cohort Collaboration on Research and Design of IeDEA," *JAMA Netw Open*. 2021 Feb 1;4(2):e2037512
183. Satre DD, Levine-Hall T, Sterling SA, Young-Wolff KC, Lam JO, Alexeeff S, Hojilla JC, Williams A, Justice AC, Sterne J, Cavassini M, Bryant KJ, Williams EC, **Horberg MA**, Volberding P, Weisner C, Silverberg MJ. Satre DD, et al., "The relationship of smoking and unhealthy alcohol use to the HIV care continuum among people with HIV in an integrated health care system" *Drug Alcohol Depend*. 2021 Feb 1;219:108481
184. Kim NH, Newcomb CW, Carbonari DM, Roy JA, Torgersen J, Althoff KN, Kitahata MM, Rajender Reddy K, Lim JK, Silverberg MJ, Mayor AM, **Horberg MA**, Cachay ER, Kirk GD, Sun J, Hull M, John Gill M, Sterling TR, Kostman JR, Peters MG, Moore RD, Klein MB, Lo Re V 3rd, The North American Aids Cohort Collaboration On Research F, Of IeDEA, "Risk of Hepatocellular Carcinoma with Hepatitis B Viremia among HIV/Hepatitis B Virus-Coinfected Persons in North America." *Hepatology*, 2021 Mar 29 (e-pub ahead of print)
185. Coburn SB, Shiels MS, Silverberg MJ, **Horberg MA**, Gill MJ, Brown TT, Visvanathan K, Connor AE, Napravnik S, Marcus JL, Moore RD, Mathews WC, Mayor AM, Sterling TR, Li J, Rabkin CS, D'Souza G, Lau B, Althoff KN; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epidemiology Databases to Evaluate AIDS, "Secular Trends in Breast Cancer Risk among Women with HIV Initiating ART in North America," *J Acquir Immune Defic Syndr*., 2021 May 1;87(1):663-670
186. Rahman V, **Horberg M**, Hu H, Vupputuri S, "Implementation of a Plant-Based Nutrition Program in a Large Integrated Health Care System: Results of a Pilot Program," *J Primary Care and Community Health*, 2021; January-December 12: 21501327211053198.
187. Monroe A, Levy M, Greenberg A, Keruly J, Moore R, **Horberg M**, Kulie P, Mohanraj B, Kumar P, Castel A, on behalf of the DC Cohort Executive Committee, "Integrase Inhibitor Prescribing Disparities in the DC and Johns Hopkins HIV Cohorts," *Open Forum Infectious Diseases*, 2021; July 27:8(8):ofab388.
188. McGinnis K, Justice A, Moore R, Silverberg M, Althoff K, Karris M, Lima V, Crane H, **Horberg M**, Klein M, Gange S, Gebo K, Mayor A, Tate J, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA and Veterans Aging Cohort Study, "Discrimination and Calibration of the VACS Index 2.0 for Predicting Mortality among People with HIV in North America," *Clinical Infectious Diseases*, 2021; e-pub ahead of print
189. Edwards J, Cole S, Breger T, Rudolph J, Filiatreau L, Buchacz K, Humes E, Rebeiro P, D'Souza G, Gill MJ, Silverberg M, Mathews C, **Horberg M**, Thorne J, Hall HI, Justice A, Marconi V, Lima V,

Bosch R, Sterling T, Althoff K, Moore R, Saag M, Eron J, “Mortality among Persons Entering HIV Care Compared with the General US Population,” *Annals of Internal Medicine*, 2021; 174(4): 1197-1206.

190. Simon G, Platt R, Watanabe J, Bindman A, London A, **Horberg M**, Hernandez A, Califf R, “When Can we Rely on Real-World Evidence to Evaluate New Medical Treatments?,” *Clinical Pharmacology & Therapeutics*, 2021; e-pub ahead of print
191. Simon G, Bindman A, Dreyer N, Platt R, Watanabe J, **Horberg M**, Hernandez A, Califf R, “When Can We Trust Real-World Data to Evaluate New Medical Treatments?,” *Clinical Pharmacology & Therapeutics*, 2021; e-pub ahead of print
192. Davy-Mendez T, Napravnik S, Eron J, Cole S, Van Duin D, Wohl D, Gebo K, Moore R, Althoff K, Poteat T, Gill MJ, **Horberg M**, Silverberg M, Nanditha N, Thorne J, Berry S, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA, “Current and Past Immunodeficiency are Associated with Higher Hospitalization Rates among Persons on Virologically Suppressive Antiretroviral Therapy for up to 11 Years,” *Journal Infectious Diseases*, 2021; 224(4): 657-666.
193. Kasaie P, Stewart C, Humes E, Gerace L, Zhang J, Silverberg MJ, **Horberg M**, Rebeiro PF, Hyle E, Lima V, Wong C, Gill MJ, Gebo K, Moore, Kitahata M, Althoff K, “Projecting the Age-Distribution of Men who have Sex with Men Receiving HIV Treatment in the United States,” *Annals of Epidemiology*, 2021; October 7:S1047-2797(21)00281-7.
194. Nadison M, Flamm L, Roberts A, Staton T, Wiener L, Locke J, Bullock E, Loftus B, Carpenter C, Sadler M, **Horberg M**, “Kaiser Permanente’s Good Health & Great Hair Program: Partnering with Barbershops and Beauty Salons to Advance Health Equity in West Baltimore, Maryland,” *Journal of Public Health Management Practice*, 2021; e-pub ahead of print
195. Kim H, Nance R, LoRe V, silverberg M, Franco R, Sterling T, **Horberg M**, Althoff K, Justice A, Moore R, Klein M, Crane H, Delaney J, Kitahata M, “Development and Validation of a Model for Prediction of End-Stage Liver Disease in People with HIV,” *JAIDS*, 2022; 89(4):396-404.
196. Park L, McGinnis K, Gordon K, Justice3 A, Leyden W, Silverberg M, Skarbinski J, Jefferson C, **Horberg M**, Certa J, Napravnik S, Edwards J, Westreich D, Bastarache L, Gangireddy S, Benning L, D’Souza G, William C, Althoff K, “SARS-CoV-2 testing and positivity among persons with and without HIV in United States Cohorts,” *JAIDS*, 2022, Feb 21; e-pub ahead of print
197. Gold R, Bunce A, Davis J, Nelson J, Cowburn S, Oakley J, Carney S, **Horberg M**, Dearing J, Melgar G, Bulkley J, Seabrook J, Cloutier H, “I Didn’t Know You Could Do That:’ A Pilot Assessment of EHR Optimizaiton Training,” *ACI Open*, 2021 (In Press)
198. Althoff K, Stewart C, Humes E, Zhang J, Gerace L, Boyd C, Wong C, Justice A, Gebo K, Thorne J, Rubstova A, **Horberg M**, Silverberg M, Leng S, Rebeiro P, Moore R, Buchacz K, Kasale P, “The Shifting Age Distribution of People with HIV Using Antiretroviral Therapy in the United States, 2020 to 2030,” *AIDS*, 2022; 36(3):459-471.
199. Coburn S, Humes E, Lang R, Stewart C, Hogan B, Gebo K, Napravnik S, Edwards J, Browne L, Park L, Justice A, Gordon K, **Horberg M**, Certa J, Watson E, Jefferson C, Silverberg M, Skarbinski J, Leyden W, William C, Althff, “Analysis of Postvaccination Breakthrough COVID-19 Infections among Adults with HIV in the United States,” *JAMA Network Open*, 2022; Jun1: 5(6):e2215394
200. Go A, Reynolds K, Avula H, Towner W, Hechter R, **Horberg M**, Vupputuri S, Leong T, Leyden W, Harrison T, Lee K, Sung S, Silverberg M, “Human Immunodeficiency Virus Infection and Variation in Heart Failure Risk by Age, Sex, and Ethnicity: The HIV HEART Study,” *Mayo Clinic Proceedings*, 2022; 97(3):465-479.

201. Qian Y, Moore R, Coburn S, Davy-Mendez T, Akgun K, McGinnis K, Silverberg M, Colasanti J, Cachay E, **Horberg M**, Rabkin C, Jacobson J, Gill M, Mayor A, Kirk G, Gebo K, Nijhawan A, Althoff K, "Association of the VACS Index with Hospitalization among People with HIV in the NA-ACCORD," *JAIDS*, 2022; 89(1):9-18.
202. Lam J, Lee C, Gilsanz P, Hou C, Leyden W, Satre D, Flamm J, Towner W, **Horberg M**, Silverberg M, "Comparison of Dementia Incidence and Prevalence between Individuals with and without HIV Infection in Primary Care from 2000 to 2016," *AIDS*, 2022; 36(3): 437-445.
203. Althoff K, Stewart C, Humes E, Zhang J, Gerace L, Boyd C, Wong C, Justice A, Gebo K, Thorne J, Rubstova A, **Horberg M**, Silverberg M, Leng S, Rebeiro P, Moore R, Buchacz K, Kasale P, "The Shifting Age Distribution of People with HIV Using Antiretroviral Therapy in the United States, 2020 to 2030," *AIDS*, 2022; 36(3):459-471.
204. Young J, LoRe V, Kim H, Sterling T, Althoff K, Gebo K, Gill M, **Horberg M**, Mayor A, Moore R, Silverberg M, Klein M, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA, "Do Contemporary Antiretrovirals Increase the Risk of Eng-Stage Liver Disease? Signals from Patients Starting Therapy in the North American AIDS Cohort Collaboration on Research and Design," *Pharmacoepidemiology and Drug Safety*, 2022; 31(2):214-224.
205. Akselrod H, Byrne M, Lundberg J, Czeresnia JM, Lucar J, Secco A, Levy M, Monroe A, Castel A, **Horberg M**, Doshi R, Rivasplata H, Squires L, Parenti D, Benator D, on behalf of the DC Cohort Executive Committee, "Improvements in Virologic Control and PWH Over Time: Narrowing the Gap Between those with and without STIs," *AIDS and Behavior*, 2022; e-pub ahead of print.
206. Coburn S, Lang R, Zhang J, Palella F, **Horberg M**, Mancilla J, Gebo K, Galaviz K, Gill MJ, Sivlerberg M, Hulgán T, Elion R, Justice A, Moore R, Althoff, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA, "Statins Utilization in Adults with HIV: The Treatment Gap and Predictors of Statin Initiation," *JAIDS*, 2022; e-pub ahead of print.
207. Muiru A, Madden E, Scherzer R, **Horberg M**, Sivlerberg M, Klein M, Mayor A, Gill MJ, Napravnik S, Crane H, Marconi V, Koethe J, Abraham A, Althoff K, Lucas G, Moore R, Shlipak M, Estrella M, "Effect of Adopting the New Race-Free 2021 Chronic Kidney Disease Epidemiology Collaboration Estimated Glomerular Filtration Rate Creatinine Equation on Racial Differences in Kidney Disease Progression among People with Human Immunodeficiency Virus: An Observational Study," *Clinical Infectious Diseases*, 2022; e-pub ahead of print
208. Lang R, Gill MJ, Coburn S, Grossman J, Gebo K, **Horberg M**, Mayor A, Sivlerberg M, Willig A, Justice A, Klein M, Bosch R, Rabkin C, Hogan B, Thorne J, Moore R, Althoff K, for the North American AIDS Cohort Collaboration on Research Design (NA-ACCORD) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA), "The Changing Prevalence of Anemia and Risk Factors in People with HIV in North America Who Have Initiated ART, 2007-2017," *AIDS*, 2022; e-pub ahead of print
209. Avula H, Ambrosy A, Silverberg M, Reynolds K, Towner W, Hechter R, **Horberg M**, Vupputuri S, Leong T, Leyden W, Harrison T, Lee K, Sung SH, Go A, "Human Immunodeficiency Virus Infection and Risks of Morbidity and Death in Adults with Incident Heart Failure," *European Heart Journal (Open)*, 2021 Dec 1;1(3):oeab040.
210. Byrne M, Akselrod H, Monroe A, **Horberg M**, Lucar J, Castel A, Denyer R, Doshi R, Secco A, Squires L, Schroffter S, Benator D, on behalf of the DC Cohort Executive Committee, "Identifying geographic areas of Washington DC with increased potential for sexual HIV transmission among People with HIV with STIs and concurrent elevated HIV RNA: Data from the DC Cohort," *Open Forum Infectious Diseases*, 2022; Mar 18;9(5):ofac139.

211. Lea A, Leyden W, Sofrygin O, Marafino B, Skarbinski J, Napravnik S, Agil D, Augenbraun M, Benning L, **Horberg M**, Jefferson C, Marconi V, Park L, Gordon K, Bastarache L, Gangireddy S, Althoff K, Coburn S, Gebo K, Lang R, Williams C, Silverberg M, "HIV Status, Tenofovir Exposure, and the Risk of Poor COVID-19 Outcomes: Real World Analysis from 6 United States Cohorts Prior to Vaccine Rollout," *Clinical Infectious Diseases*, 2023; 2023 Mar 2;ciad084; online ahead of print
212. Lang R, Humes E, Coburn S, **Horberg M**, Fathi L, Watson E, Jefferson C, Park L, Justice A, Gordon K, Napravnik S, Edward J, Browne L, Silverberg M, Skarbinski J, Leyden W, Stewart C, Hogan B, Gebo K, Williams C, Althoff K, for the Corona-Infectious-Virus Epidemiology Team (CIVETs) of the NA-ACCORD of IeDEA, "Analysis of severe illness after SARS-CoV-2 breakthrough infection in people with and without HIV in the United States," *JAMA Network Open*, 2022; 2022 Oct 3;5(10):e2236397
213. Jetsupphasuk M, Hudgens M, Lu H, Cole S, Edwards J, Adimora A, Althoff K, Silverberg M, Rebeiro P, Lima V, Marconi V, Sterling T, **Horberg M**, Gill MJ, Kitahata M, Moore D, Lang R, Gebo K, Rabkin C, Eron J, "Optimizing Treatment for Human Immunodeficiency Virus to Improve Clinical Outcomes Using Precision Medicine," *American Journal of Epidemiology*, 2023; 2023 Mar 15: kwad057
214. Jaurretche M, Byrne M, Happ LP, Levy M, **Horberg M**, Greenberg A, Castel AD, Monroe AK; DC Cohort Executive Committee, "HIV Care Continuum Outcomes among Recently Diagnosed People with HIV (PWH) in Washington, DC," *Epidemiol Infect.* 2023; 2023 Jan 30;151:e45
215. Zalla LC, Cole SR, Eron JJ, Adimora AA, Vines AI, Althoff KN, Silverberg MJ, **Horberg MA**, Marconi VC, Coburn SB, Lang R, Williams EC, Gill MJ, Gebo KA, Klein M, Sterling TR, Rebeiro PF, Mayor AM, Moore RD, Edwards JK, "Association of Race and Ethnicity with Initial Prescription of Antiretroviral Therapy Among People with HIV in the US," *JAMA*. 2023; 2023 Jan 3;329(1):52-62
216. Lang R, Hogan B, Zhu J, McArthur K, Lee J, Zandi P, Nestadt P, Silverberg MJ, Parcesepe AM, Cook JA, Gill MJ, Grelotti D, Closson K, Lima VD, Goulet J, **Horberg MA**, Gebo KA, Camoens RM, Rebeiro PF, Nijhawan AE, McGinnis K, Eron J, Althoff KN; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA), "The Prevalence of Mental Health Disorders in People with HIV and the Effects on the HIV Care Continuum," *AIDS*, 2023; 2023 Feb 1;37(2):259-269
217. Davy-Mendez T, Napravnik S, Hogan B, Eron J, Gebo K, Althoff K, Moore R, Silverberg M, **Horberg M**, Gill MJ, Rebeiro P, Karris M, Klein M, Kitahata M, Crane H, Nijhawan A, McGinnis K, Thorne J, Lima V, Bosch R, Colasanti J, Rabkin C, Lang R, Berry S, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA, "Hospital Readmissions among Persons with HIV in the United States and Canada, 2005-2018: A Collaboration of Cohort Studies," *Journal of Infectious Diseases*, 2023 (e-pub ahead of print)
218. Zalla L, Cole S, Eron J, Adimora A, Vines A, Althoff K, Marconi V, Gill MJ, **Horberg M**, Silverberg M, Rebeiro P, Lang R, Kasaie P, Moore R, Edward J, "Evaluating Clinic-Based Interventions to Reduce Racial Differences in Mortality among People with HIV in the United States," *Journal of Infectious Diseases*, 2023; Jul 12; jias263 (e-pub ahead of print)
219. Monroe A, Kulie P, Byrne M, Wilbourn B, Barth S, Resnik J, Huebner D, **Horberg M**, Castel A, Greenberg A, for the DC Cohort Executive Committee, "Psychosocial Impacts of the COVID-19 Pandemic from a Cross-Sectional Survey of People Living with HIV in Washington, DC," *AIDS Research and Therapy*, 2023; 20(1):27.
220. Kim J, Newcomb C, Caronari D, Torgerson J, Althoff K, Kitahata M, Klein M, Moore R, Reddy KR, Silverberg M, Mayor A, **Horberg M**, Cachay E, Lim J, Gill MJ, Chew K, Sterling T, Hull M, Seaberg E, Kirk G, Coburn S, Lang R, McGinnis K, Gebo K, Napravnik S, Kim H, Le Re V, "Hepatitis B Cascade among People with HIV/HBV Coinfection in the North American AIDS Cohort Collaboration on Research and Design, 2012-2016," *PLOS One*, 2023; Sep 1;18(9):e0290889.



221. Mallipeddi V, Levy M, Byrne M, Monroe A, Happ L, Moeng L, Castel A, **Horberg M**, Wilcox R, “Evaluation of New Hypertension Guidelines on the Prevalence and Control of Hypertension in a Clinical HIV Cohort: A Community-Based Study,” *AIDS Research and Human Retroviruses*, 2023; e-pub ahead of print
222. Castel A, Barth S, Wilbourn B, **Horberg M**, Monroe A, Greenberg A, for the DC Cohort Executive Committee, “Trends in COVID-19 Vaccine Hesitancy and Uptake among Persons Living with HIV in Washington, DC,” *JAIDS*, 2023; 94(2): 124-134.

### **In Press**

1. **Horberg M**, Hu H, Bhatia M, Leyden W, Hechter R, Lam J, Lea A, Yuan Q, Go A, Towner W, Silverberg M, “Modifiable Risk Factors, Tenofovir Use, and Incident Chronic Kidney Disease among People with and without HIV Infection,” *JAIDS*, 2023 (Submitted)
2. Adams A, Lee C, Escobar G, Bayliss E, Callaghan B, Grant R, **Horberg M**, Schmittiel J, Trinacty C, Gilliam L, Kim E, Hejazi N, Neugebauer R, “Machine Learning Approach to Estimate Risk of Lower Extremity Complications among Adults Newly Diagnosed with Diabetic Polyneuropathy,” *Medical Care*, 2023 (Submitted)
3. Barth S, Saulters K, Balba G, Monroe A, **Horberg M**, Kumar P, Greenberg A, Castel A, “Mixed Methods Analysis of Telehealth Experience, Satisfaction, and Quality of Care during the COVID Pandemic Among Persons with HIV in Washington, DC,” *AIDS and Behavior*, 2023 (In Press)
4. Silverberg M, Levine T, Lea A, Williams A, Alexeeff S, Bryant K, Cavassini M, Flamm J, Hare B, Ingle S, Justice A, Lam J, Sterling S, **Horberg M**, Satre D, “Cardiovascular Disease Risk Factor Control in People with and Without HIV,” *Journal of General Internal Medicine*, 2023 (Submitted)
5. Lang R, Coburn S, Gill MJ, Grossman J, Geob K, **Horberg M**, Mayor A, Justice A, Bosch R, Silverberg M, Rabkin C, Sterling T, Thorne J, Moore R, Althoff K, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA, “The Association of Anemia with Survival among People with HIV Following Antiretroviral Initiation in the NA-ACCORD 2007-2016,” *JAIDS*, 2023 (Submitted)

### **Publications as a Collaborator (not as a named Author)**

1. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Nguyen BY, Teppler H; BENCHMRK Study Teams. Raltegravir with optimized background therapy for resistant HIV-1 infection. *N Engl J Med*. 2008 Jul 24;359(4):339-54.
2. Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen BY; BENCHMRK Study Teams. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. *N Engl J Med*. 2008 Jul 24;359(4):355-65.
3. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H; MOTIVATE Study Teams. Maraviroc for previously treated patients with R5 HIV-1 infection. *N Engl J Med*. 2008 Oct 2;359(14):1429-41.
4. Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E; MOTIVATE 1 and MOTIVATE 2 Study Teams.

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. *N Engl J Med.* 2008 Oct 2;359(14):1442-55

5. Hauschild, B., Onaga, L., Miller, V. (on behalf of Horberg, M., et. al.), *Metrics and Evaluation Measures for Monitoring the Implementation of Routine HIV Testing in the U.S.*, Report of a Forum for Collaborative HIV Research Roundtable, December 14, 2009, available and [www.hivforum.org](http://www.hivforum.org)
6. Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Katlama C, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Clotet B, Zhao J, Wan H, Rhodes RR, Strohmaier KM, Barnard RJ, Isaacs RD, Nguyen BY; BENCHMRK Study Teams. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase iii trials. *Clin Infect Dis.* 2010 Feb 15;50(4):605-12.
7. Althoff K, Justice A, Gange S, Deeks S, Saag M, Silverberg M, Gill M, Lau B, Napravnik S, Tedaldi E, Klein M, Gebo K for NA-ACCORD, "Virologic and Immunology Response to HAART, by Age and Regimen Class," *AIDS*, 2010; 24:000 e-pub ahead of print
8. Institute of Medicine, *HIV and Disability: Updating the Social Security Listings*, National Academies Press, 2010.
9. Institute of Medicine, *HIV Screening Access to Care: Exploring Barriers and Facilitators to Expanded HIV Testing*, National Academies Press, 2010.
10. Institute of Medicine, *Monitoring HIV Care in the United States: Indicators and Data Systems*, National Academies Press, 2012.
11. Eron J, Steigbigel RT, Cooper DA, Clotet B, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Strohmaier KM, Wan H, Barnard RJ, Nguyen BY, Teppler H, for the BENCHMRK Study Teams, "Efficacy and Safety of Raltegravir for treatment of HIV for 5 Years in the BENCHMRK Studies: Final Results of Two Randomised, Placebo-Controlled Trials," *Lancet Infectious Diseases*, 2013; 13: 587-596.
12. Toh S, Reichman M, Graham D, Hampp C, Zhang R, Butler M, Iyer A, Rucker M, Pimentel M, Hamilton J, Lendle S, Fireman B; for the Mini-Sentinel Saxagliptin-AMI Surveillance Writing Group, "Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study," *Diabetes Care*, 2017; e-pub ahead of print
13. Engels E, Yanik E, Wheeler W, Gill J, Shiels M, Dubrow R, Althoff K, Silverberg M, Brooks J, Kitahata M, Goedert J, Grover S, Mayor A, Moore R, Park L, Rachlis A, Sigel K, Sterling T, Thorne J, Pfeiffer R, North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS; North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS, "Cancer-Attributable Mortality among People with Treated Human Immunodeficiency Virus Infection in North America," *Clinical Infectious Diseases*, 2017; 65(4): 636-643.

### **Other Publications**

1. **Horberg M**, Schatz B. [letter] Battling HIV on many fronts. *N Engl J Med.* 1998 Jan 15;338(3):198
2. **Horberg M**. Book Review: Fenway Guide to Lesbian, Gay, Bisexual and Transgender Health. *Annals Internal Medicine*, 2008; 149(5): p.368.

### **Abstracts and Oral Presentations**

1. Rice H, Zolopa A, **Horberg M**, Klein D. Abstract 558-T, "Correlation of Phenotypic Resistance and Virologic Response to Indinavir/Ritonavir Boosted Regimens", 9<sup>th</sup> Conference of Retrovirus and Opportunistic Infections, February, 2002
2. **Horberg M**, Klein D, Luu T, Sinn K, Abstract 681, "Long Term Efficacy of Indinavir/Ritonavir in Highly ART Experienced Patients", IDSA, October, 2001 (published in *Clinical Infectious Diseases*)
3. **Horberg M**, Klein D, Luu T, Sinn K, Abstract TuPeB4442, "Durability of Nelfinavir-Based HAART," XIV International AIDS Conference, July, 2002, Barcelona
4. Rice H, Zolopa A, **Horberg M**, Klein D, Coram, M, Condra, JH, Hellmann, N, King, H, Bates, M, Abstract TuPeB4603, "Virologic Response to Ritonavir-Boosted Indinavir Regimens Correlates with Baseline Phenotypic Resistance to Indinavir," XIV International AIDS Conference, July, 2002, Barcelona, Spain
5. Szumiloski J, Wilson E, Jensen R, Campo R, Rice H, Zolopa A, **Horberg M**, Klein D, Abstract 155, "Relationship Between Phenotypic Susceptibility to Indinavir and Virologic Response to Indinavir-Ritonavir Containing Regimens Following Failure of a Previous Protease Inhibitor," 11<sup>th</sup> International HIV Drug Resistance Workshop, July, 2002, Seville, Spain
6. Klein D, Hurley L, **Horberg M**, Abstract H-1154, "Appendicitis in HIV Patients Before and After HAART," 42<sup>nd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, September, 2002.
7. Delorenze G, **Horberg M**, Karter A, Ferrara A, Quesenberry C, Tsai A, Oral Presentation 44, "Incidence and Prevalence of Diabetes Mellitus among HIV-Infected Patients in Northern California's Largest HMO," 10<sup>th</sup> Conference on Retrovirus and Opportunistic Infections, February, 2003.
8. DeWeese J, Delaney A, Klein D, **Horberg M**, Abstract 721, "Surgical Treatment of HIV Lipohypertrophy (LH) of Head and Neck (H/N)," 10<sup>th</sup> Conference on Retrovirus and Opportunistic Infections, February, 2003.
9. Szumiloski J, Wilson H, Campo R, Miller N, Rice H, Zolopa A, Klein D, **Horberg M**, Hellmann, N, Bates, M, Condra, J, Abstract 603, "Determination of an Indinavir Susceptibility Cutoff for Indinavir-Ritonavir Containing Regimens," 10<sup>th</sup> Conference on Retrovirus and Opportunistic Infections, February, 2003.
10. Fessel W, Rhee S, Hurley L, Slome S, Klein D, **Horberg M**, Flamm, J, Follansbee, S, Shafer, R, "High-Level Dual (NRTI and PI) and Triple Class Multidrug Resistance in a Large Health Maintenance Organization: Prevalence, Risk Factors, and Response to Salvage Therapy," 7<sup>th</sup> International Resistance Workshop, July, 2003.
11. **Horberg M**, Hurley L, Klein D, Follansbee S, Flamm J, Green G, Abstract 82 (oral), "Surgical Outcomes of HIV+ Patients in the Era of HAART," 11<sup>th</sup> Conference of Retrovirus and Opportunistic Infections, February, 2004.
12. Fessel W, Rhee S, Hurley L, Nguyen D, Slome S, Smith S, Klein D, **Horberg M**, Flamm J, Follansbee S, Gonzales M, Shafer R., Abstract 690, "High-Level Dual and Triple Class Multi-drug Resistance in a Large Health Maintenance Organization: Prevalence, Risk Factors, and Response to Salvage Therapy," 11<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, February, 2004.
13. Hurley L, Klein D, **Horberg M**, "Exploration of Factors Contributing to Reduced CHD Risk Among a Large Cohort of HIV-1 Infected Patients," 8<sup>th</sup> International Workshop on HIV Observational Databases, March, 2004.
14. **Horberg M**, Klein D, Yu J, Sinn K, Abstract BTuPp2066, "Effect of Tenofovir on Renal Function in a "Real World" Clinic Setting," XV International AIDS Conference, July, 2004, Bangkok, Thailand.

15. Delorenze G, **Horberg M**, Karter A, Ferrara, A, Quesenberry, C, Tsai, A, Abstract 70, "Impaired Glucose Metabolism in a Large HIV+ Clinic Population," 9th International HIV Observational Database Conference, April, 2005.
16. Silverberg M, **Horberg M**, Hurley L, Klein D, Abstract MoPe15.1C07, "Demographic and Clinical Parameters Associated with HIV Quality Indicators During the HAART Era in the Largest Integrated Health Care System in California," 3<sup>rd</sup> IAS Conference on HIV Pathogenesis and Treatment, July, 2005.
17. **Horberg M**, Holodniy M, Hornberger J, Hurley L, Marrufo G, Robertus K, Deyton L, Bersoff-Matcha S, Tonwer W, Weinberg W, Antoniskis D, Mogyoros M, Dodge W, Kovach D, Abstract 760, "Comparison of the Two Largest Integrated HIV Healthcare Delivery Systems in the United States", 43<sup>rd</sup> Infectious Disease Society Of America, October, 2005.
18. Klein D, Hurley L, Quesenberry C, Silverberg M, **Horberg M**, Sidney S, Abstract 737, "Hospitalizations for CHD and MI Among Northern California HIV+ and HIV- Men: Changes in Practice and Framingham Risk Scores," 13<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, Denver, CO, February 2006
19. Bersoff-Matcha S, Silverberg M, Hurley L, Towner W, Weinberg W, Antoniskis D, Mogyoros M, Dodge W, Dobrinich R, **Horberg M**, Abstract 887, "Differences in Response to HAART by Gender and HCV Co-infection Status in a Large HMO Setting," 13<sup>th</sup> Conference on Retroviruses and Opportunistic Infections,, Denver, CO, February 2006
20. **Horberg M**, Hurley L., Silverberg M, Hurley L, Kinsman CJ, Selby J, Oral Presentation 5, "Predictors of Improved Adherence and Disease Markers in HIV+ Patients Starting a New Regimen—A Retrospective Cohort Analysis," NIMH/IAPAC Conference on HIV Treatment Adherence, March, 2006
21. **Horberg M**, Silverberg M, Hurley L, Kinsman DJ, Abstract TuPe0107, "Impact of HIV Clinical Pharmacists on Antiretroviral Adherence and Clinical Outcomes in ARV Experienced Patients," XVI International AIDS Conference, August, 2006.
22. **Horberg M**, Silverberg M, Hurley L, Towner W, Klein D, Bersoff-Matcha S, Weinberg W, Antoniskis D, Mogyoros M, Dodge W, Dobrinich R, Kovach D, Abstract TuPe0117, "Effects of Depression and SSRI use on Adherence and HIV Clinical Outcomes in Patients Taking Combination Antiretroviral Therapy," XVI International AIDS Conference, August, 2006.
23. Silverberg M, Leyden W, **Horberg M**, Delorenze G, Klein D, Quesenberry C, Abstract TuPe0135, "Older Age, Therapy Adherence, Comorbidities and Variable Response to antiretrovirals," XVI International AIDS Conference, August 2006.
24. Silverberg M, Leyden W, **Horberg M**, Delorenze G, Klein D, Quesenberry C, Abstract WePe0177, "Older age associated with reduced tolerability of antiretrovirals," XVI International AIDS Conference, August 2006.
25. Klein D, Hurley L, Silverberg M, **Horberg M**, Quesenberry C, Sidney S, Abstract 807, "Surveillance Data for Myocardial Infarction Hospitalizations among HIV+ and HIV- Northern Californians: 1994-2006," 14<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, February 2007.
26. Silverberg M, Leyden W, **Horberg M**, Hurley L, Go A, Quesenberry C, Klein D, Abstract 814, "Lipid-Lowering Therapy Responses in HIV+ and HIV- Dyslipidemic Patients Enrolled in a Large Integrated Healthcare Delivery System," 14<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, February 2007.
27. Silverberg S, Leyden W, Klein D, Quesenberry C, **Horberg M**, Abstract P-150, "Advanced Antiretroviral Treatment Failure among Kaiser Permanente Patients," 2<sup>nd</sup> International Conference on HIV Treatment Adherence, March 2007.

28. Silverberg MJ, Leyden W, Quesenberry C, **Horberg M**, Abstract WEPEB107, "Influence of race/ethnicity on adherence to and effectiveness of antiretroviral therapy among patients with access to care," 4th International AIDS Society Conference, Sydney, Australia, July 2007
29. **Horberg M**, Klein D, Hurley L, Silverberg M, Towner W, Antoniskis D, Kovach D, Mogyoros M, Blake W, Dobrinich R, Dodge W, Abstract WEPEB025, "Efficacy and Safety of Non-Boosted to Ritonavir-Boosted Atazanavir among Antiretroviral Naïve Patients," 4th International AIDS Society Conference, Sydney, Australia, July 2007.
30. Fessel J, Rhee S, Klein D, Hurley L, Liu T, Follansbee S, Slome S, Flamm J, **Horberg M**, Shafer R, Abstract 892, "Low Risk of Initial ART Failure in Patients with Wild Type HIV-1 by Standard Genotypic Resistance Testing," 15<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, February 2008.
31. **Horberg M**, Tang B, Towner W, Bersoff-Matcha S, Klein D, Silverberg M, Chen W, Hurley L, Chang J, Blank J, Abstract 975, "Effect of Tenofovir on Renal Function in Patients Using HAART," 15<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, February 2008.
32. **Horberg M**, Tang B, Towner W, Bersoff-Matcha S, Klein D, Silverberg M, Chen W, Hurley L, Change J, Blank J, Oral Abstract 44, "Two Versus Three Pill HAART—Does it Make a Difference?," 3<sup>rd</sup> IAPAC/NIMH Conference on HIV Treatment Adherence, March, 2008.
33. Mosen D, **Horberg M**, Gullion C, Meenan R, Roblin D, Oral Abstract THPDB105, "Effect of Fixed-Dosed Combination Therapies on HAART Initiation among an ARV Naïve Population in a Managed Care Setting," XVII International AIDS Conference, August, 2008.
34. Meenan R, O'Keeffe-Rosetti M, Kimes T, Leyden W, Antoniskis D, Saget B, Young T, **Horberg M**, Abstract TUPE0236, "Excess Prevalence-based costs of multiple HAART regimens among HIV-infected patients in a US health maintenance organization," XVII International AIDS Conference, August, 2008.
35. Towner W, Klein D, Follansbee S, Yu K, Kerrigan H-L, **Horberg M**, Abstract TUPE0115, "Pilot Study of Switching Enfuvirtide to Raltegravir in HIV-1 Positive Patients Well Controlled on an Enfuvirtide Based Regimen," XVII International AIDS Conference, August, 2008.
36. **Horberg M**, Ranatunga D, Silverberg M, Klein D, Abstract L-648, "Syphilis in Northern California," 48th ICAAC/46th IDSA Meeting, October, 2008.
37. Silverberg M, Leyden W, Chao C, Xu L, Tang B, **Horberg M**, Klein D, Towner W, Abrams D, Oral Abstract 30, "Infection-related Non-AIDS-Defining Cancer Risk in HIV-Infected and –Uninfected Persons," 16<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, February, 2009.
38. Hurley L, Leyden W, Xu L, Silverberg M, Chao C, Tang B, Towner W, **Horberg M**, Klein D, Abstract 710, "Updated Surveillance of Cardiovascular Event Rates among HIV-infected and HIV-uninfected Californians, 1996 to 2008," 16<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, February, 2009.
39. Chao C, Xu L, Abrams D, Tang B, Leyden W, **Horberg M**, Towner W, Klein D, Silverberg M, Abstract 871, "Prognosis of Non-Hodgkin's Lymphoma in HIV-Infected Patients," 16<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, February, 2009.
40. Rhee SY, Fessel W, Klein D, Hurley L, Flamm J, Follansbee S, **Horberg M**, Shafer R., "Virologic Outcome Associated with Genotype-Guided Therapy in Patients with Transmitted HIV-1 Drug Resistance (TDR) Between 2003 and 2006," XVIII International HIV Drug Resistance Workshop, June, 2009.

41. **Horberg M**, Hurley L, Towner W, Gambatese R, Klein D, Antoniskis D, Weinberg W, Quesenberry C, Johnson M, Silverberg M, Abstract CDB125, "Antiretroviral Adherence and Achieving Maximal Viral Control by Regimen Class," 5<sup>th</sup> IAS Conference, Cape Town, SA, July 2009.
42. Tran T, Ray G, Saddier P, **Horberg M**, Yawn B, Li Y, Castillo A, Silverberg M, Quesenberry C, Habel L, "Incidence and Risk Factors of Herpes Zoster in Cancer Patients," 47<sup>th</sup> Annual Meeting of the Infectious Disease Society of America, Philadelphia, 2009.
43. Blanco J, Rhee S, **Horberg M**, Follansbee S, Hurley L, Liu T, Klein D, Fessel W, Shafer R, "Virologic Response to Raltegravir Salvage and Maintenance Therapy," 47<sup>th</sup> Annual Meeting of the Infectious Disease Society of America, Philadelphia, 2009.
44. **Horberg M**, Postlethwaite D, Hung Y-Y, Hurley L, Sinclair F, Lantzman E, Schwarz E, Armstrong MA, Abstract 932, "Use of Contraception among HIV-Infected Women of Reproductive Age in Northern California," 17<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, San Francisco, 2010.
45. Althoff K, Gange S, Klein M, **Horberg M**, Bosch R, Hogg R, Zhang J, Moore R on behalf of NA-ACCORD, Abstract 982, "Late Presentation for HIV Care in the US and Canada," 17<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, San Francisco, 2010.
46. Silverberg S, Xiu L, Chao C, Leyden W, **Horberg M**, Klein D, Towner W, Quesenberry C, Neugebauer R, Abrams D, Oral Abstract 28, "Immunodeficiency, HIV RNA Levels, and Risk of Non-AIDS Defining Cancers," 17<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, San Francisco, 2010.
47. Lo J, Hurley L, Go A, Klein D, **Horberg M**, Lee G, Quesenberry C, Silverberg M, Abstract 715, "Impact of HIV Infection on Outcomes Following Coronary Revascularization," 17<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, San Francisco, 2010.
48. Golub E, Deeks S, Hunt P, Martin J, Zhang J, **Horberg M**, Gebo K, Kitahata M, Rachlis A, Greenblatt R, Saag M, Kirk G, Sterling T, Napravnik S, Moore R, Gange S, for the NA-ACCORD, "Prevalence of extreme virologic and immunologic control in North American HIV treatment sites," 2010 International Workshop on HIV Observational Databases (IWHOD), Sitges, Spain, 2010.
49. Armstrong, MA, Postlethwaite D, Hung YY, **Horberg M**, Sinclair F, Lantzman E, Schwarz EB. "Use of Contraception by Women with Chronic Medical Conditions," 18<sup>th</sup> Annual Congress of American Medical Women's Association, Washington, DC, 2010.
50. **Horberg M**, Chao C, Hurley L, Tang B, Quesenberry C, Towner W, Silverberg M, "Prescription of a New Class of Antiretroviral Medication (ARV) in a Large Integrated Healthcare System," NIMH/IAPAC Treatment Adherence Conference, Miami, 2010 (Poster)
51. **Horberg M**, Hurley L, Towner W, Gambatese R, Klein D, Antoniskis A, Weinberg W, Kadlecik P, Remmers C, Dobrinich R, Quesenberry C, Johnson M, Silverberg M, "Antiretroviral Adherence and HIV RNA Control Quality Measurement," NIMH/IAPAC Treatment Adherence Conference, Miami, 2010 (Oral Abstract)
52. Towner W., Xu L., Silverberg M., Leyden W., Chao C., Klein D., Hurley L., Quesenberry C., **Horberg, M**, Abstract TUAB0102, "Fatal and Non-fatal in HIV-infected versus HIV-uninfected Persons Enrolled in Kaiser Permanente California, A Large Managed Care Organization," XVIII International AIDS Conference, Vienna, Austria, July, 2010 (Oral Abstract).
53. Althoff K, Gebo K, Gange S, Klein M, Brooks J, Hogg R, Bosch R, **Horberg M**, Saag M, Kitahata M, Eron J, Napravnik S, Rourke S, Gill MJ, Rodriguez B, Sterling T, Deeks S, Martin J, Jacobson L, Kirk G, Collier A, Benson C, Silverberg M, Goeder J, McKaig R, Thorne J, Rachlis A, Moore R, Justice A for the NA-ACCORD of IeDEA, "CD4 Count at Presentation for HIV Care in the United States and Canada:

Are those Over 50 Years More Likely to have a Delayed Presentation,” International Workshop on HIV and Ageing, 2010

54. **Horberg M**, Hurley L, Towner W, Allerton M, Tang B, Catz S, Silverberg M, Quesenberry C, Abstract 1131, “Impact of Provider Experience Characteristics on HIV-Related Outcomes among cART Naive,” Infectious Disease Society of America 48<sup>th</sup> Annual Meeting, Vancouver, Canada, October, 2010
55. Silverberg M, Klein D, Leyden W, Chao C, **Horberg M**, Towner W, Quesenberry C, Neugebauer R, Abrams D, Van Den Eeden S, Abstract 1097, “Prostate Cancer Risk and Use of Prostate Specific Antigen Tests among HIV-infected and HIV-uninfected Men,” Infectious Disease Society of America 48<sup>th</sup> Annual Meeting, Vancouver, Canada, October, 2010
56. Silverberg M, Leyden W, L, Chun C, **Horberg M**, Klein D, Towner W, Quesenberry C, Neugebauer R, Abrams A, Oral Abstract 81, “Antiretroviral therapy use and risk of cancer in HIV patients,” 18<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, February, 2011 (Oral Presentation)
57. Klein D, Leyden W, Xu L, Chao C, **Horberg M**, Towner W, Hurley L, Quesenberry C, Silverberg M, “Contribution of Immunodeficiency to Coronary Heart Disease: Cohort Study of HIV-infected and HIV-uninfected Kaiser Permanente Members,” 18<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, February, 2011 (Oral Poster)
58. Justice A, Modur S, Tate J, Althoff K, Gange S, Jacobson L, Gebo K, Kitahata M, **Horberg M**, Napravnik S for the NA-ACCORD of IeDEA, “A Prognostic Index for those Aging with HIV: Extension of the VACS Index to those on Combination Antiretroviral Therapy,” 18<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, February, 2011
59. Althoff K, Rebeiro P, Gill MJ, **Horberg M**, Eron J, Napravnik S, Anastos K, Bosch R, Moore R, Gange S, for NA-ACCORD of IeDEA, “Trends in HIV Viral Load among Adults in Clinical Care in the US and Canada, 1997-2007,” 18<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, February, 2011
60. Chao C, Xu L, Abrams D, Towner W, **Horberg M**, Leyden, Silverberg M, Abstract 869, “Statin Use and Risk of Non-Hodgkin’s Lymphoma in HIV-infected Persons,” 18<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, February 2011
61. Althoff K, Gange S, Klein M, Brooks J, Hogg R, Bosch R, **Horberg M**, Saag M, Moore R, for the NA-ACCORD, “Characteristics of Late Presenters and Timing of Antiretroviral Therapy Initiation,” 15<sup>th</sup> International Workshop on HIV Observational Databases, Prague, Czech Republic, March, 2011
62. Rebeiro P, Althoff K, Gill MJ, Brooks J, Buchacz K, Gebo K, Martin J, **Horberg M**, Hogg R, Thorne J, Klein M, Sterling T, Moore R, Gange S, for the NA-ACCORD, Abstract 15\_132, “Sustained Care after Presentation among HIV-Infected Adults in North America: The Importance of Churn in Observational Cohorts,” 15<sup>th</sup> International Workshop on HIV Observational Databases, Prague, Czech Republic, March, 2011
63. Meenan R, **Horberg M**, Silverberg M, Chao C, Williams A, Keast E, Leyden W, Xu L, Tang B, Antoniskis D, Towner W, Abstract C-A5-01, “Development of Prevention Index Methodology for Application to HIV Quality of Care,” 17<sup>th</sup> Annual HMO Research Network Conference, Boston, MA, March, 2011
64. **Horberg M**, Hurley L, Towner W, Allerton M, Tang B, Catz S, Silverberg M, Quesenberry C, “Determination of Optimized Multidisciplinary Care Teams for Maximal Antiretroviral Therapy Adherence,” 6<sup>th</sup> International Conference on HIV Treatment and Prevention Adherence, Miami, FL, May, 2011 (Oral presentation)

65. **Horberg M**, Hurley L, Towner W, Allerton M, Tang B, Catz S, Silverberg M, Quesenberry C, Abstract MOPE464, "Impact of Provider Characteristics on HIV-related Outcomes among Antiretroviral Experienced Patients," The 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, July, 2011
66. **Horberg M**, Hurley L, Towner W, Allerton M, Tang B, Catz S, Silverberg M, Quesenberry C, Abstract MOPE422, "Determination of Optimal Multidisciplinary Care Teams (MDCT) for Achieving HIV RNA Below Limits of Quantification (BLQ)," The 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, July, 2011
67. Gomez V, Somkin, C, Potter M, Ackerson L, Dao T, **Horberg M**, Walsh J, "Development, Implementation, and Dissemination of the FLU-FIT Program in Kaiser Permanente Northern California," APHA 139<sup>th</sup> Annual Meeting, Washington, DC, October, 2011
68. **Horberg M**, Hurley L, Towner, W, Gambatese R, Klein D, Antoniskis D, Weinberg W, Kadlecik P, Kovach D, Mogyoros M, Remmers C, Quesenberry C, Silverberg M, Johnson M, Abstract 484, "HIV Quality Metrics: Association between Retention in Care and Maximal Viral Control," 49<sup>th</sup> Annual Meeting of the Infectious Diseases Society of America, October, 2011
69. Towner W, Leyden W, Chao C, Xu L, **Horberg M**, Klein D, Tang B, Hurley L, Silverberg M, Oral abstract 1393, "Rhabdomyolysis in HIV-infected versus HIV-uninfected Persons Enrolled in Kaiser Permanente California," 41<sup>st</sup> Annual Meeting of the Infectious Disease Society of America, Boston, Massachusetts, October 2011
70. **Horberg M**, Hurley L, Klein D, Silverberg M, Quesenberry C, Mugavero M, Abstract 1129, "Early Missed Office Visits Post-HIV Diagnosis and Mortality in a Large Healthcare System," 19<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, March, 2012
71. Hanna D, Gebo K, Hessol N, **Horberg M**, Kirk G, Kitahata M, Napravnik S, Sterling T, Willig J, and Gange S for the NA-ACCORD of IeDEA, "Disparities in Rates of HIV treatment Initiation and Viral Load Suppression across US States, 2001-2007," 19<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, March, 2012
72. Silverberg M, Chao C, Leyden W, Xu L, Yu J, **Horberg M**, Klein D, Towner W, Quesenberry C, Abrams D, "Cancer Stage, Age at Diagnosis and Survival Comparing HIV+ and HIV- Individuals with Common Non-AIDS-Defining Cancers," 19<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, March, 2012
73. Delorenze G, **Horberg M**, Silverberg M, Tsai A-L, Quesenberry C, "Time Trends in Methicillin-resistant staphylococcus aureus (MRSA) Infection Rates Comparing HIV-infected Patients with the General (HIV-uninfected) Patient Population," 19<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, March, 2012
74. Justice A, Modur S, Tate J, Althoff K, Gange S, Jacobson L, Gebo K, Kitahata M, **Horberg M**, Napravnik S for the NA-ACCORD of IeDEA, "A Prognostic Index for those Aging with HIV: Extension of the VACS Index to Those on Combination Antiretroviral Therapy," 19<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, March, 2012
75. Hanna DB, Gebo KA, Hessol NA, **Horberg M**, Kirk GD, Kitahata MM, Napravnik S, Sterling TR, Willig JH, and Gange SJ for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the IeDEA, "Disparities in Rates of HIV Treatment Initiation and Viral Load Suppression across U.S. States, 2001-2007," 19<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, March, 2012



76. Althoff K, Rebeiro P, Gill MJ, **Horberg M**, Eron J, Napravnik S, Anastos K, Bosch R, Moore R, Gange S for the NA-ACCORD of IeDEA, "Trends in HIV Viral Load among Adults in Clinical Care in the US and Canada, 1997-2007," 19<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, March, 2012
77. Klein D, Leyden W, Xu L, Chao C, **Horberg M**, Towner W, Hurley L, Quesenberry C, Silverberg M, Abstract 060, "Contribution of Immunodeficiency to Coronary Heart Disease: Cohort Study of HIV-infected and HIV-uninfected Kaiser Permanente Members," Epidemiology and Prevention/Nutrition, Physical Activity, and Metabolism 2012 Scientific Sessions, San Diego, CA, March, 2012
78. Silverberg M, Leyden W, Stewart C, Ralston J, **Horberg M**, Carzasty S, Grothaus L, Catz S, "Change in Adherence to Antiretrovirals After Initial Use of an Electronic Share Medical Record among HIV-Infected Individuals," HMO Research Network Conference, Seattle, WA, April, 2012
79. Rebeiro PF, Althoff KN, Gill MJ, Krentz H, Gebo KA, **Horberg M**, Hogg RS, Thorne JE, Sterling TR, and Gange SJ for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA, "Factors Associated with Absence from HIV Clinical Care Among Black Patients in the NA-ACCORD: Application of Beta-binomial and Transition Models to Observational Cohort Data," 2012 International Workshop on HIV Observational Databases (IWHOD), Athens, Greece, May, 2012.
80. **Horberg M**, Hurley L, Towner W, Allerton M, Tang B, Catz S, Silverberg M, Quesenberry C, "Impact on Emergency Department (ED) and Hospitalization Utilization among Optimized Multidisciplinary Care Teams Associated with Maximal Antiretroviral Adherence," 7<sup>th</sup> International Conference on Treatment and Prevention Adherence, Miami Beach, FL, June, 2012
81. Catz S, Amico KR, Balderson B, Hogan P, **Horberg M**, Mahoney C, McClure J, Silverberg M, Ralston J, "Individually Tailoring a Health Information Technology Adherence Intervention Using Patient-Reported Web Survey Responses," 7<sup>th</sup> International Conference on Treatment and Prevention Adherence, Miami Beach, FL, June, 2012
82. Rebeiro P, Althoff K, Gill J, Krentz H, Gebo K, Martin J, **Horberg M**, Hogg R, Thorne J, Klein M, Sterling T, Moore R, Gange S for the NA-ACCORD of IeDEA, "Modeling Clinical Retention in the North American HIV Population," 2012 Society for Epidemiologic Research, Minneapolis, MN, June, 2012
83. Meenan R, **Horberg M**, Silverberg M, Chao C, Williams A, Vogt T, Antoniskis D, Towner W, Keast E, Leyden W, Xu L, Vijayadeva V, "Developing New Quality Measures for HIV Care Using the Electronic Medical Record," XIX International AIDS Conference, Washington, DC, July, 2012
84. Hanna D, Buchacz K, Hessol N, **Horberg M**, Jacobson L, Kitahata M, Moore R, Napravnik S, Patel P, Gebo K, Willig J, Sterling T, Kirk G, Collier A, Ohl M, Thorne J, Gange S for the NA-ACCORD of IeDEA, "Association between State AIDS Drug Assistance Program Features and Treatment Initiation in Clinically Eligible US HIV-Infected Persons," XIX International AIDS Conference, Washington, DC, July, 2012
85. Rebeiro P, Althoff K, Gill J, Krentz H, Gebo K, Martin J, **Horberg M**, Hogg R, Thorne J, Klein M, Rourke S, Sterling T, Moore R, Gange S for the NA-ACCORD of IeDEA, "Patterns and Predictors of Absences from HIV Care in North America (2000-2008)," XIX International AIDS Conference, Washington, DC, July, 2012
86. Abraham A, Lau B, Estrella M, Szczech L, Rourke S, Rodriguez B, Rachlis A, Chirag P, Napravnik S, Moore R, Klein M, Kitahata M, Jing J, **Horberg M**, Harris M, Eron J, Crane H, Bosch R, Benson C, Anastos K, Althoff K, Lucas G, for the NA-ACCORD of IeDEA, "Tenofovir-Associated Kidney Function decline with a PI-based Versus NNRTI-based Regimen," XIX International AIDS Conference, Washington, DC, July, 2012

87. Althoff K, Buchacz K, Hall I, Zhang J, Hanna D, Rebeiro P, Gange S, Moore R, Kitahata M, Gebo K, Martin J, Justice A, **Horberg M**, Hogg R, Sterling T, Cescon A, Klein M, Thorne J, Crane H, Mugavero M, Napravnik S, Kirk G, Jacobson L, Rodriguez B, Brooks J for the NA-ACCORD of IeDEA, "Trends in Antiretroviral Therapy Use, HIV RNA Plasma Viral Load, and CD4 T-Lymphocyte Counts at Death among HIV-Infected Persons in Care in the United States, 2000-2008, XIX International AIDS Conference, Washington, DC, July, 2012
88. Hanna D, Buchacz K, Hessel N, **Horberg M**, Jacobson L, Kitahata M, Moore R, Napravnik S, Patel P, Gebo K, Willig J, Sterling T, Kirk G, Collier A, Ohl M, Thorne J, Gange S for the NA-ACCORD of IeDEA, "Trends in Antiretroviral Therapy Initiation and Virologic Suppression among Newly Clinically-Eligible HIV-Infected Individuals in North America, 2001-2009," XIX International AIDS Conference, Washington, DC, July, 2012
89. **Horberg M**, Hurley L, Towner W, Gambatese R, Klein D, Antoniskis D, Kadlecik P, Kovach D, Remmers C, Silverberg M, Abstract 1033, "HIV Spectrum of Engagement Cascade in a Large Integrated Care System by Gender, Age, and Methodologies," 20<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, March 2013
90. Althoff K, Rebeiro P, **Horberg M**, Buchacz K, Gebo K, Sterling T, Kitahata M, Justice A, Moore R, for the North American AIDS Cohort Collaboration on Research and Design, Abstract 1026, "Application of Indicators to Monitor US Department of Health and Human Services-Funded HIV Services in the NA-ACCORD," 20<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, March, 2013
91. Rebeiro P, **Horberg M**, Gebo K, Brooks J, Buchacz K, Silverberg M, Gill MJ, Moore R, Althoff K, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), Abstract 1035, "No meaningful difference between retention indicators from US government agencies within the largest HIV Cohort Collaboration in North America," 20<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, March, 2013
92. Althoff K, Abraham A, Estrella M, Crane H, Freeman A, Gill J, Golub E, **Horberg M**, Jacobson L, Kitahata M, McKaig R, Palella F, Parikh C, Moore R, Jing Y, Rodriguez B, Eron J, Napravnik S, Buchacz K, Silverberg M, Mayor A, Krishnasami Z, Lucas G, for the NA-ACCORD of IeDEA, "Incidence of End Stage Renal Disease in the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD)," 7<sup>th</sup> International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Kuala Lumpur, Malaysia, July, 2013
93. Silverberg M, Leyden W, Stewart C, Ralston J, **Horberg M**, Grothaus L, Catz S, "Antiretroviral therapy adherence and use of an electronic shared medical record among HIV-positive Individuals," 46<sup>th</sup> Annual Society for Epidemiologic Research Meeting, Boston, MA, June, 2013
94. Althoff K, Rebeiro P, Hanna D, Hogg R, Brooks J, Abraham A, **Horberg M**, Buchacz K, Gil MJ, Mayor A, Thorne J, Sterling T, Williams C, Rachlis A, Burchell A, for the North American AIDS Cohort Collaboration on Research and Design, "Measures on the Map: A Geographical Display of HIV Infection and Care Indicators," 17<sup>th</sup> International Workshop on HIV Observational Databases, Cavtat, Croatia, April, 2013
95. Silverberg M, Hurley L, Prasad A, Zaroff J, Klein D, **Horberg M**, Go A, Lo J, Abstract 75, "Mortality Following Hospitalization for Acute Coronary Syndrome among HIV+ and HIV- Patients," 43<sup>rd</sup> Annual Meeting of the Infectious Disease Society of America, San Francisco, California, October, 2013
96. Silverberg M, Hurley L, Prasad A, Zaroff J, Klein D, **Horberg M**, Go A, Lo J, "Similar outcomes for HIV+ and HIV- patients within three years following hospitalization for acute coronary syndrome," *American Heart Association Annual Meeting*, October, 2013, Washington, DC

97. Marcus J, Leyden W, Chao C, Chow F, **Horberg M**, Hurley L, Klein D, Quesenberry C, Towner W, Silverberg M, "HIV Infection and Immunodeficiency as Risk Factors for Ischemic Stroke," 21<sup>st</sup> Conference on Retroviruses and Opportunistic Infections, Boston, MA, March, 2014
98. Maeda J, Lee K, **Horberg M**, "Comparative Health Systems Research among Integrated Delivery Systems and Managed Care Organizations: A Systematic Review," HMO Research Network Conference, Phoenix, AZ, April, 2014
99. Yehia B, Rebeiro P, Althoff K, Gange S, Samji H, **Horberg M**, Napravnik S, Gebo K, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Age Impacts the Association of Retention in Care and Viral Suppression," 21<sup>st</sup> Conference on Retroviruses and Opportunistic Infections, Boston, MA, March, 2014
100. Klein D, Leyden W, Chao C, **Horberg M**, Towner W, Hurley L, Quesenberry C, Silverberg, M, "No Difference in Incidence of Myocardial Infarction for HIV+ and HIV- Individuals in Recent Years," 21<sup>st</sup> Conference on Retroviruses and Opportunistic Infections, Boston, MA, March, 2014 (Accepted)
101. Rebeiro PF, Althoff KN, Lau B, **Horberg M**, Mugavero MJ, Samji H, Napravnik S, Silverberg MJ, Rachlis A, and Gange SJ for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the IeDEA, "Labs are Imperfect Proxies of Encounters: Retention Trends in the Largest North American HIV Cohort," 18th International Workshop on HIV Observational Databases (IWHOD), Sitges, Spain, March, 2014
102. Rebeiro P, Gange S, **Horberg M**, Abraham A, Napravnik S, Samji H, Yehia B, Curriero F, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "The geography of HIV clinical retention in the United States: regional trends in the NA-ACCORD," 18th International Workshop on HIV Observational Databases (IWHOD), Sitges, Spain, March, 2014
103. **Horberg M**, Hurley L, Klein D, Towner W, Kadlecik P, Finnegan C, Mogyoros M, Matyas RJ, Brachman P, Silverberg M, "Methodology Issues in HIV Quality Performance Measures," XX International AIDS Conference, Melbourne Australia, July, 2014
104. **Horberg M**, Hurley L, Klein D, Towner W, Kadlecik P, Finnegan C, Mogyoros M, Matyas RJ, Brachman P, Silverberg M, "The HIV Care Cascade Measured Over Multiple Time Periods Varies by Time Period and Method," XX International AIDS Conference, Melbourne Australia, July, 2014 (Accepted as Oral Abstract)
105. Silverberg M, Muthulingam D, Leyden W, Yee A, Marcus J, **Horberg M**, Klein D, Towner W, Chao C, Baxter R, "Incidence and Risk Factors of Invasive Pneumococcal Disease Among HIV-positive and HIV-negative Adults," XX International AIDS Conference, Melbourne Australia, July, 2014
106. **Horberg M**, Hurley L, Klein D, Towner W, Kadlecik P, Finnegan C, Mogyoros M, Matyas R, Brachman P, Blank J, Ellis C, Silverberg M, Abstract 88, "The HIV Care Cascade Measured over Multiple Time Periods Varies by Age and Gender," IDWeek 2014 (Annual Meeting of IDSA/HIVMA/SHEA/PIDS), Philadelphia, PA, October, 2014 (Accepted as Oral Abstract)
107. Goddard K, Cardoza N, Croen L, Feigelson H, Harris K, Honda S, **Horberg M**, Jonas C, Koebnick C, Nguyen M, Owen-Smith A, Rowell S, Schaefer C, Smith KS, Somkin C, Vu J, Wrenn M, Yonehara C, Emmons K, "The Kaiser Permanente Biobank: A Multi-Region, Multi-Ethnic Resource Linking Specimens and Electronic Medical Records for Broad Research in an Integrated Health Care Delivery System," American Society of Human Genetics Annual Meeting, San Diego, California, October, 2014
108. Gold R, Esterberg E, Hollombe C, Vakarcis T, Arkind J, Tran M, Burdick T, Faer M, Johnson M, **Horberg M**, "Guideline-discordant imaging for low back pain in primary care: A cross-system analysis," NAPCRG annual conference, New York, NY , November 21-25 2014

109. Marcus J, Leyden W, Chao C, Xu L, Quesenberry C, Klein D, Towner W, **Horberg M**, Silverberg M, "Differences in Response to Antiretroviral Therapy by Sex and Hepatitis C Infection Status," 2<sup>nd</sup> Conference on Overcoming Health Disparities in the Bay Area: Focus on HIV and HCV, San Francisco, CA, 2015
110. Rebeiro P, Yehia B, Gebo K, Lau B, Mayer K, **Horberg M**, Kitahata M, Gill J, Sterling T, Gange S, "Continuous Retention Predicts Viral Suppression Across the US and Canada," 22<sup>nd</sup> Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2015
111. Wong C, Gange S, **Horberg M**, Kirk G, Rachlis A, Gill J, Thorne J, Hogg R, Goedert J, Althoff K, "Age-Related Morbidities Among HIV-Infected Adults from 2000-2010," 22<sup>nd</sup> Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2015
112. Calikins K, Eron J, Abraham A, Buchacz K, **Horberg M**, Tate J, Napravnik S, Moore R, Bosch R, Lau B, "CD4 Reconstitution is Related to CD4 at Effective Antiretroviral Initiation," 22<sup>nd</sup> Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2015
113. Feigelson H, Croen L, Goddard K, Honda S, **Horberg M**, Koebnick C, Owne-Smith A, Rowell S, Schaefer C, Somkin C, Emmons K, "The Kaiser Permanente Biobank: A Multi-Region Resource Linking Specimens and Electronic Medical Records for Broad Research in an Integrated Health Care Delivery System," HMO Research Network Conference, Long Beach, CA, 2015
114. Marcus J, Leyden W, Neugebauer R, Chao C, Xu L, Quesenberry C, Klein D, Towner W, **Horberg M**, Silverberg M, "Use of Abacavir and Risk of Cardiovascular Disease among HIV-Infected Individuals: A Marginal Structural Model Approach," Society for Epidemiological Research Annual Meeting, 2015
115. Rebeiro P, Abraham A, **Horberg M**, Gill J, Yehia B, Silverberg M, Rachlis A, Samji H, Sterling T, Gange S, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Racial Differences in Discontinuity and Re-Entry into HIV Care after Antiretroviral Therapy Initiation in the U.S. and Canada," 2015 International Workshop on HIV Observational Databases," Sitges Spain, 2015
116. Abraham A, Althoff K, Jing Y, Estrella M, Wang R, Wester W, Kitahata M, Bosch R, Crane H, Eron J, Gill MJ, **Horberg M**, Justice A, Klein M, Mayor A, Moore R, Palella F, Parikh C, Silverberg M, Golub E, Jacobson L, Napravnik S, Lucas G, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Use of Tenofovir in HIV-Infected Patients at Risk for End Stage Renal Disease," 2015 International Workshop on HIV Observational Databases," Sitges Spain, 2015
117. Althoff K, Jing Y, Gebo K, Klein M, Kitahata M, Gill J, Dubrow R, Silverberg J, Samji H, Wong C, Rachlis A, **Horberg M**, Lau B, Moore R, Gange S, Lucas G, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Aging Better with HIV: Using the Population Attributable Fraction to Inform Interventions to Reduce End-Stage Renal Disease in HIV+ Adults," 2015 International Workshop on HIV Observational Databases, Sitges Spain, 2015
118. **Horberg M**, Hurley L, Klein D, Towner W, Kadlecik P, Remmers C, Gambatese R, Blank J, Ellis C, Silverberg M, "The HIV Care Cascade Measured Over Multiple Time Periods Varies by Race and Ethnicity," NIMH/IAPAC Treatment Adherence Conference, Miami, FL, 2015 (Oral Abstract)
119. Johnson A, Kirk G, Drummond B, O'Cleirigh C, Hogg R, Brooks J, Moore R, **Horberg M**, Rourke S, Mayor A, Gill MJ, Martin J, Napravnik S, Eron J, Kitahata M for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Cigarette Smoking and the Relationship with Retention in HIV Care, 2008-2010," Society for Research on Nicotine and Tobacco Annual Meeting, Philadelphia, PA, 2015
120. Calkins K, Eron J, Abraham A, Buchacz K, **Horberg M**, Tate J, Napravnik S, Moore R, Bosch R, Lau B, "CD4 Reconstitution is related to CD4 at Effective Antiretroviral Treatment Initiation," 8<sup>th</sup> IAS Conference on HIV Pathogenesis, Treatment, and Prevention, Vancouver, BC, July, 2015

121. **Horberg M**, Blank J, Rubenstein K, Hurley L, Marcus J, Klein D, Kadlecik P, Silverberg M, Abstract 1035, "Differences in Viral Suppression by Frequency and Type of Healthcare Visits," 23<sup>rd</sup> Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2016
122. Marcus J, Chao C, Leyden W, Xu L, Quesenberry C, Klein D, Towner W, **Horberg M**, Silverberg M, "Narrowing the Gap in Life Expectancy for HIV+ Compared with HIV- Individuals," 23<sup>rd</sup> Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2016 (Oral Abstract)
123. Rebeiro P, Mugavero M, **Horberg M**, Mayer K, Martin J, Kitahata M, Abraham A, Moore R, Sterling T, Gange S, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Regional Differences in Ancillary Care Services for HIV-Infected Adults in the US: Policy Implications," 20th International Workshop on HIV Observational Databases, Budapest, Hungary, April, 2016
124. Rebeiro P, Althoff K, Lau B, Gill J, Abraham A, **Horberg M**, Kitahata M, Yehia B, Samji H, Brooks J, Buchacz K, Napravnik S, Silverberg M, Rachlis A, Gebo K, Sterling T, Moore R, Gange S, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Laboratory Measures are Imperfect Proxies of Primary Care Encounters: Implications for Quantifying Clinical Retention among HIV-Infected Adults in North America," 23<sup>rd</sup> Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2016
125. Althoff K, Kucirka L, Abraham A, Massie A, Kitahata M, **Horberg M**, Fischer M, Silverberg M, Butt A, Boswell S, Martin J, Durand C, Locke J, Moore R, Lucas G, "The Racial Survival Paradox in HIV+ End-stage Renal Disease (ESRD) Patients," 23<sup>rd</sup> Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2016
126. Wang R, Althoff K, Kucirka L, Abraham A, Massie A, Kitahata M, **Horberg M**, Fischer M, Silverberg M, Butt A, Boswell S, Martin J, Durand C, Locke J, Moore R, Lucas G, "Short-term Renal Impact of tenofovir among HIV-infected Patients in North America," 23<sup>rd</sup> Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2016
127. Desir FA, Rebeiro PF, Moore RD, Crane HM, Gabler K, Margolick JB, Bosch R, **Horberg M**, Silverberg MJ, and Althoff KN. Retention, ART use, and viral suppression among women linked to HIV care in the United States," 2017 Conference on Retroviruses and Opportunistic Infections (CROI), 2017, Seattle, Washington (Oral)
128. Desir F, Rebeiro P, Moore R, Crane H, Gabler K, Margolick J, Bosch R, **Horberg M**, Silverberg M, Althoff K, Abstract 1002, "Retention, ART Use, and Viral Suppression among Young Adults Newly Linked to HIV Care," 2017 Conference on Retroviruses and Opportunistic Infections (CROI), 2017, Seattle, Washington
129. Althoff K, **Horberg M**, Eron J, Gange S, Crane H, Justice A, Kitahata M, Margolick J, Eyawo O, Moore R, Abstract 2096, "The Large Gap between Statin Eligibility and Prescription among HIV+ in North America," 2017 Conference on Retroviruses and Opportunistic Infections (CROI), 2017, Seattle, Washington
130. Althoff K, Palella F, Gebo K, Gange S, Rabkin C, Thorne J, **Horberg M**, Klein D, Kitahata M, Moore R, Abstract 2022, "Impact of Smoking, Hypertension & Cholesterol on Myocardial Infarction in HIV+ Adults," 2017 Conference on Retroviruses and Opportunistic Infections (CROI), 2017, Seattle, Washington
131. Sun J, Althoff KN, Jing Y, **Horberg M**, Buchacz K, Gill MJ, Justice AC, Rabkin C, Goedert JJ, Thorne J, Mayor A, Crane HM, Kitahata MM, Klein MB, Kirk GD, "Risk of hepatocellular carcinoma among persons living with HIV and viral hepatitis co-infection in the United States and Canada, 1996-2009," 2017 International Workshop on HIV Observational Databases, Lisbon, Portugal, April, 2017 (Oral)

132. Althoff KN, Wong C, Hogan B, Desir F, Zhang J, Modur S, You B, Liu B, Jing Y, **Horberg M**, Rebeiro PF, Justice AC, Kitahata MM, Gange SJ. "Using observation windows for improving ascertainment assumptions in clinical cohort studies: Illustration of ascertaining diabetes outcomes.," 2017 International Workshop on HIV Observational Databases, Lisbon, Portugal, April, 2017
133. Tartof S, Arduino J, Wei R, Hsu J-W, Rubenstein K, Hu H, **Horberg M**, Derose S, Rodriguez C, "The Additional Impact of Chronic Kidney Disease on Cardiovascular Outcomes and Death among HCV Patients," EASL The International Liver Congress, Barcelona, Spain, April, 2016
134. Tartof S, Arduino J, Wei R, Hsu J-W, Rubenstein K, Hu H, **Horberg M**, Derose S, Rodriguez C, "The Additional Impact of Hepatitis C Infection on Cardiovascular Outcomes and Death among Patients with Chronic Kidney Disease," Digestive Disease Week, San Diego, California, 2016
135. Desir F, Rebeiro P, Moore R, Crane H, Gabler K, Margolick J, Bosch R, **Horberg M**, Silverberg M, Althoff K, "Retention, ART Use, and Viral Suppression among Women Linked to HIV Care in the United States," CFAR 2016 Joint Symposium on HIV Research in Women, Washington, DC, 2016
136. **Horberg M**, Blank J, Rubenstein K, Kadlecik P, Hurley L, Silverberg M, "Changes in Antiretroviral Therapy (ART) and Maximal Viral Suppression over Time by Age, Gender, Race/Ethnicity, and HIV Risk among HIV-Infected Patients in an Integrated Health System in the United States," 9<sup>th</sup> IAS Conference on HIV Science (IAS 2017), Paris France, July, 2017
137. **Horberg M**, Blank J, Rubenstein K, Hurley L, Kadlecik P, Klein D, Silverberg M, "Do HIV Viral Suppression Rates Vary by Frequency and Type of Healthcare Visits in an Integrated Health System," 12<sup>th</sup> International Conference on HIV Treatment and Prevention Adherence (Adherence 2017), Miami, Florida, June 2017
138. Althoff K, Moore R, Gill J, **Horberg M**, Justice A, Kitahata M, Klein M, Desir F, Mathews W, Mayor A, Rebeiro P, Silverberg M, Gange S, Hogg R, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Life Expectancy in Key Populations of Adults with HIV in the US and Canada," CROI 2018, Boston MA (Accepted)
139. Benson E-M, Klein M, Kitahata M, Moore R, Lo Re V, **Horberg M**, Mayor A, Silverberg M, Kim N, Eron J, Cachay E, Hull M, Gange S, Althoff K, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Survival after End-Stage Liver Disease in Adults with HIV: Findings from the NA-ACCORD," CROI 2018, Boston MA (Accepted)
140. Lo Re V, Newcomb C, Carbonari D, Roy J, Kitahata M, Lim J, Silverberg M, Mayor A, **Horberg M**, Cachay E, Hull M, Moore R, Klein M, Kim HN, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Determinants of Liver Complications among HIV/Hepatitis B-Coinfected Patients," CROI 2018, Boston MA (Accepted)
141. Desir F, Lesko C, Moore R, **Horberg M**, Rebeiro P, Gill J, Kitahata M, Silverberg M, Levison J, Klein M, Mayor A, Justice A, Althoff K, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Trends in Unsuppressed HIV RNA after Linkage to Care among Key Populations," CROI 2018, Boston MA (Accepted)
142. Desir F, Lesko C, Moore R, Silverberg M, Rebeiro P, **Horberg M**, Kitahata M, Crystal S, Mayor A, Klein M, Justice A, Gill J, Althoff K, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Age-Dependent Racial/Ethnic Disparities in Longitudinal HIV Care Indicators," CROI 2018, Boston MA (Accepted)
143. Althoff K, Buchacz K, Moore R, Gange S, Kitahata M, **Horberg M**, Bosch R, Lee J, Martin J, Mayer K, Patel P, Rabkin C, Thorne J, Brooks J, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Rate and Risk of Transmissible HIV RNA ( $\geq 1500$  copies/mL) Among Adults on ART," CROI 2018, Boston MA (Accepted Oral)

144. Poteat T, Hanna D, Rebeiro P, Klein M, Silverberg M, Eron J, **Horberg M**, Kitahata M, Mathews W, Mattocks, Mayor A, Rich A, Moore R, Althoff K, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Characterizing the HIV Continuum of Care for Transgender Women in North America," CROI 2018, Boston MA
145. **Horberg M**, Blank J, Rubenstein K, Hurley L, Kadlecik P, Klein D, Silverberg M, "Beyond Viral Suppression: Broadening Quality Measures (QM) for Total HIV Patient Care," Abstract 633, CROI 2018, Boston MA
146. Rebeiro PP, Gange S, Althoff K, Berry S, **Horberg M**, Rachlis B, Yehia B, Moore R, Sterling T, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Impact of Medicaid Expansion under the Affordable Care Act ("Obamacare") on HIV Viral Suppression Outcomes in the United States, 2008-2015," 22<sup>nd</sup> International Workshop on HIV and Hepatitis Observational Databases (IWHOD), 2018, Fuengirola, Spain
147. Powers-Happ, Monroe A, Young H, Ma Y, Greenberg A, Benator D, **Horberg M**, Castel A, on behalf of the DC Cohort Executive Committee, Abstract 342, "The Impact of Glycemic Control on CD4 Cell Count in Persons Living with HIV and Diabetes Mellitus—Washington, DC," IDSA 2019, Washington, DC
148. Jaurrette M, Byrne M, Powers-Happ L, Levy M, **Horberg M**, Castel A, Monroe A, on behalf of the DC Cohort Executive Committee, Abstract 1320, "HIV Care Continuum Outcomes among Newly Diagnosed PLWY in Washington, DC," IDSA 2019, Washington, DC
149. Monroe A, Levy M, Greenberg A, Moore R, Keruly J, **Horberg M**, Mohanraj BS, Kumar P, Castel A, on behalf of the DC Cohort Executive Committee, Abstract 2492, "Differences between Individuals Currently Taking Integrase Inhibitor (INSTI)-Based Therapy and Those Not Taking INSTIs in the Era of INSTIs as Recommended First-Line Therapy," IDSA 2019, Washington, DC
150. Silverberg MJ, Sarovar V, Satre D, Alexeeff S, Leyden W, Lam J, Anderson A, Hechter R, Hu H, Marcus J, Towner W, Yuan Q, **Horberg M**, "Excess Mortality in Persons with HIV After Cancer Diagnosis," CROI 2020, Boston MA
151. Lam J, Leyden W, Reynolds K, **Horberg M**, Towner W, Hechter R, Vupputuri S, Leong T, Avula H, Harrison T, Lee K, Sung S, Neugebauer R, Go A, Silverberg M, "HIV Severity and Incident Heart Failure among Patients in a Large Healthcare System," CROI 2020, Boston MA
152. Marcus J, Leyden W, Anderson A, Hechter R, **Horberg M**, Hu H, Lam J, Towner W, Yuan Q, Silverberg MJ, "Increased Overall Life Expectancy but Not Comorbidity-Free Years for People with HIV," CROI 2020, Boston, MA
153. **Horberg M**, Leyden W, Hechter R, Lam J, Hu H, Anderson A, Marcus J, Yuan Q, Go A, Towner W, Silverberg MJ, "Modifiable Risk Factors and Incident CKD and CVD among HIV+ and HIV- Patients," CROI 2020, Boston MA
154. Lesko C, Edwards J, Jing Y, Moore R, **Horberg M**, Rebeiro R, Rich A, Silverberg MJ, Mayor A, Eron J, Crane H, Mathews WC, Althoff K, Poteat T, "Progression through the HIV Care Continuum for Transgender Women in the NA-ACCORD," CROI 2020, Boston MA
155. Oliver C, Lau B, Althoff K, Buchacz K, Crane H, Gill MJ, **Horberg M**, Mayer K, Mayor A, Moore R, Schranz A, Sterling T, Pettit A, Rebeiro P, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Mental Health and Substance Use Services and Retention in HIV Care in North America," CROI 2020, Boston MA
156. Althoff K, Brown T, Burkholder G, Crane H, Delaney J, Elion R, Galaviz K, Gange S, **Horberg M**, Palella F, Silverberg MJ, Tate J, Moore R, for the North American AIDS Cohort Collaboration on

Research and Design (NA-ACCORD), “Myocardial Infarction by Atherosclerotic Cardiovascular Disease (ASCVD) Risk Score,” CROI 2020, Boston MA

157. Rebeiro P, Jenkins C, Bian A, Lake J, Bourgi K, Althoff K, Floris-Moore M, **Horberg M**, Tate J, Willig A, Moore R, Gange S, Sterling T, Koethe J, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), “Diabetes, Weight Gain, and Integrase Inhibitor Use in North American HIV+ Persons,” CROI 2020, Boston MA
158. Davy-Mendez T, Napravnik S, Gebo K, Althoff K, Gill MJ, **Horberg M**, Mathews WC, Eron J, Martin J, Lau B, Buchacz K, Lima V, Klein M, Berry S, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), “Cause-Specific Hospitalization Trends among North American Persons with HIV 2005-2015,” CROI 2020, Boston MA
159. Lee J, Lau B, Eron J, Bosch R, Kitahata M, Fleming J, Gill MJ, Mathews WC, Sterling T, Lima V, Silverberg MJ, **Horberg M**, Althoff K, Moore R, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), “High Probability of Survival in Patients Who Maintain Viral Loads <200 Copies/mL,” CROI 2020, Boston MA
160. Akselrod H, Byrne M, Monroe A, Levy M, Denyer R, Klein A, **Horberg M**, Castel A, Doshi R, Secco A, Lucar J, Squires L, Schroeter S, Benator D, for the DC Cohort Executive Committee, “Geographic estimation of Sexual HIV Transmission Burden in the Era of U=U; Data from the DC Cohort,” CROI 2020, Boston MA
161. Levy M, Monroe A, **Horberg M**, Benator D, Castel A, for the DC Cohort Executive Committee, “Cardiovascular Risk Factors among Persons with Spontaneous Control of HIV Replication,” CROI 2020, Boston MA
162. Powers-Happ L, Monroe A, Young H, Ma Y, Greenberg A, **Horberg M**, Castel A, “Influence of HbA1C Trends on Diabetes Complications among PLWH with Diabetes,” CROI 2020, Boston MA
163. Byrne M, Monroe A, Powers-Happ L, Doshi R, **Horberg M**, Castel A, “Substance Use and Engagement in Care: A Latent Class Analysis of PLWH in DC Cohort,” CROI 2020, Boston MA
164. Kasale P, Stewart C, Humes E, Zhang J, Rebeiro P, **Horberg M**, Rich A, Silverberg M, Hyle E, Althoff K, “Age at ART Initiation in the “Treat All” Era: Results from the PEARL Model,” IWHOD 2020, Sitges, Spain
165. Lee J, Humes E, Lau B, McKaig R, Palella F, Klein M, Fleming J, Rebeiro P, Eaton E, Crane H, Mathews C, **Horberg M**, Silverberg M, Moore R, Althoff K, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA, “Cumulative Incidence of Virologic Nonsuppression following Initial Suppression: Complete Case Analysis vs. Imputation for Left-Censored HIV RNA Measurements,” IWHOD 2020, Sitges, Spain
166. Park L, McGinnis K, **Horberg M**, Jefferson C, Bastarche L, Gangireddy S, Silverberg M, Leyden W, Napravnik S, Agil D, Abraham A, D’Souza A, Althoff K, on behalf of the CIVET collaboration of the NA-ACCORD of IeDEA, “SARS-CoV-2 Testing and Positivity among Persons with & without HIV in 6 US Cohorts,” CROI 2021, Chicago, IL (Accepted)
167. Klein M, Young J, Althoff K, Cahay E, Franco R, Gill MJ, **Horberg M**, Hull M, Kim N, LoRe V, Moore R, Price J, Sebastiani G, Silverberg M, “Are Modern Antiretrovirals Hepatotoxic? Signals in Patients Starting ART in NA-ACCORD,” CROI 2021, Chicago, IL (Accepted)
168. McGinnis K, Justice A, Moore R, Silverberg M, Althoff K, Karris M, Lima V, Crane H, **Horberg M**, Klein M, Gange S, Gebo K, Mayor A, Tate J, “Calibration of the VACS Index 2.0 for Estimating Mortality among PWH in North America,” CROI 2021, Chicago, IL (Accepted)



169. Kim HN, Nance R, Whitney B, Althoff K, Moore R, Silverberg M, **Horberg M**, Mayor A, Cacay E, Hull M, Lo Re V, Klein M, Delaney J, Kitahata M, "Prediction Model for End-Stage Liver Disease among People with HIV in the NA-ACCORD," CROI 2021, Chicago, IL (Accepted)
170. Kim HN, Newcomb C, Carbonari D, Cachay E, Gill MJ, Hull M, Kostman J, Lim J, Silverberg M, **Horberg M**, Mayor A, Kitahata M, Klein M, Lo Re V, "Hepatocellular Carcinoma and HBV Viremia in HIV/HBV-Coinfected Persons in NA-ACCORD," CROI 2021, Chicago, IL (Accepted)
171. Coelho L, Jenkins C, Shepherd B, Pape J, Mejia F, Padgett D, Crabtree-Ramirez B, Grinsztejn B, Althoff K, Joethe J, Marconi V, Tien P, Willig A, McGowan C, Rebeiro P, **Horberg M**, "Weight gain Post-ART in HIV+ Latinos/AS Differs in the US, Canada, and Latin America," CROI 2021, Chicago, IL (Accepted)
172. Li J, Humes E, Hanna D, Lee J, Althoff K, Moore R, Crane H, Colasanti J, **Horberg M**, Nijhawan A, D'Souza G, Rentsch C, Gebo K, Buchacz K, "Disparities in Timely Receipt of ART Prescription in HIV Care in the U.S., 2012-2018," CROI 2021, Chicago, IL (Accepted)
173. Moeng L, Byrne M, Monroe A, Maillipedi V, , **Horberg M**, Castel A, Wilcox R, "The Association of Low Nadir CD4/CD8 with CVD and NADC in the DC Cohort," CROI 2021, Chicago, IL (Accepted)
174. Silverberg M, Levine-Hall T, Anderson A, Alexeeff S, Lam J, Hare B, Williams A, Cavassini M, **Horberg M**, "Prevention of Cardiovascular Disease in Persons with and without HIV," CROI 2021, Chicago, IL (Accepted)
175. Lam J, Gilsanz P, Lee C, Hou C, Leyden W, Satre D, Flamm J, Towner W, **Horberg M**, Silverberg M, "Dementia Incidence among ART-Treated People with HIV in a Primary Care Setting," CROI 2021, Chicago, IL (Accepted)
176. Humes E, Lee J, Li J, Hanna D, Marconi V, Colasanti J, Crane H, Kitahata M, Bosch R, Shah S, **Horberg M**, Silverberg M, Althoff K, Moore R, Buchacz K, "Trends and Disparities in Achieving Viral Suppression in the United States, 2012-2018," CROI 2021, Chicago, IL (Accepted)
177. Silverberg M, Levine-Hall T, Lea A, Leibowitz A, **Horberg M**, Hare CB, Luu M, Flamm J, Satre D, "Changes in Substance Use, Depression and Anxiety after Implementaiton of Self-Administered Screening and Follow-Up Treatment in HIV Primary Care Settings," Addiction Health Services Research Conference 2021, Boston, MA (Accepted)
178. Watson E, **Horberg M**, Jefferson C, Certa J, Althoff K, Williams C, Moore R, "Clinical Conditions Associated with PASC in Kaiser Permanente Mid-Atlantic States," CROI 2022, Denver, CO (Accepted)
179. **Horberg M**, Watson E, Jefferson C, Certa J, Althoff K, Williams C, Moore R, Post-Acute Sequelae of SARS-CoV-2: Clinical Condition Comparison in a Matched Cohort," CROI 2022, Denver, CO (Accepted as Oral Presentation)
180. Thorne J, Hanna D, Parcesepe A, Althoff K, Colasanti J, Crane H, French A, Gange S, Gebo K, Hessol N, **Horberg M**, Moore R, Silverberg M, Rebeiro P, the North American IDS Cohort Collaborion on Research and Design (NA-ACCORD) of IeDEA, "Effect of AIDS Drug Assistance Program Variability on Timely ART & Viral Suppression," CROI 2022, Denver, CO (Accepted)
181. Lang R, Althoff K, Closson K, Gerelotti D, **Horberg M**, "Prevalence of Mental Health Disorders and the Effects on the HIV Care Continuum," CROI 2022, Denver, CO (Accepted)
182. Lang R, Gill MJ, Moore R, Silverberg M, Willig A, Mayor A, Loutfy M, Klein M, Justice A, **Horberg M**, "Prevalence of Anemica and Risk Factors in People with HIV in the Modern ART Era," CROI 2022, Denver, CO (Accepted)

183. Certa J, Jefferson C, Watson E, **Horberg M**, Silverberg M, Napravnik S, Browne L, “Differences in COVID-19 Testing, Positivity, and Outcomes by Race, Sex, and Health System Setting in a Large Diverse US Cohort,” National Big Data Health Science Conference 2022, Charleston, SC (Accepted)
184. Althoff K, Silverberg M, **Horberg M**, Gordon K, Justice A, Gebo K, Certa J, Park L, McGinnia K, Freeman A, Agil D, Williams C, “Impact of Discontinuity in EHR Data Pipelines on Inferences that are Contingent upon SARS-CoV-2 Testing or Vaccination Data: Lessons Learned from the CIVETS Collaboration of 5 Healthcare Systems,” National Big Data Health Science Conference 2022, Charleston, SC (Accepted)
185. Zalla L, Cole S, Eron J, Adimora A, Vines A, **Horberg M**, Crystal S, Marconi V, William E, Mayor A, Gill MJ, Althoff K, Silverberg M, Edwards J, “Trends in Racial and Ethnic Differences in HIV Care Continuum Measures among US Adults, 1996-2019,” 24<sup>th</sup> International Workshop on HIV and Hepatitis Observational Databases, Sitges, Spain, 2022 (Accepted)
186. Lee J, Li X, Humes E, Furukawa A, Rebeiro P, Hanna D, Napravnik S, Crane H, Gill MJ, Silverberg M, **Horberg M**, Lima V, Rosenblum M, Althoff K, for the North American AIDS Cohort Collaboration on Research Design (NA-ACCORD), “Standardizing Retention in Care Estimates in the NA-ACCORD, 2010-2018,” 24<sup>th</sup> International Workshop on HIV and Hepatitis Observational Databases, Sitges, Spain, 2022 (Accepted)
187. Lang R, Coburn S, Gill MJ, **Horberg M**, Silverberg MJ, Mayor A, Bosch R, Rabkin C, Althoff K, “Association of Anemia on Non\_AIDS Defining Malignancy in People with HIV Following ART Initiation,” CROI 2023 (Accepted)
188. Castel A, Boyer S, **Horberg M**, Monroe A, on behalf of DC Cohort Executive Committee, “Modelling of Care Engagement Patterns in a Longitudinal Cohort of PWH—Washington, DC”, CROI 2023, Denver, CO (Accepted)
189. Castel A, Andersen E, Boyer S, **Horberg M**, Monroe A, on behalf of DC Cohort Executive Committee, “8-Year Care Trajectories in an Urban Cohort of PWH Receiving Care—Washington, DC”, CROI 2023, Denver, CO (Accepted)
190. Coburn S, Humes E, Lang R, **Horberg M**, Moore R, Silverberg M, D’Souza G, Park L, Gill MJ, Justice A, Young M, Rabkin C, Napravnik S, Althoff K, “Risk Factors for Five-Year Mortality in People with HIV After Cancer Diagnosis,” CROI 2023, Denver, CO (Accepted)
191. Deshmukh A, Lin Y-Y, Damgaciuglu H, Chao E, Nyitray A, Althoff K, Coburn S, Silverberg M, Gebo K, Moore R, **Horberg M**, Napravnik S, Cachay E, Onawane S, Sigel K, “Recent and Projected Trends in Anal Cancer Incidence Among Persons with HIV in the US,” CROI 2023, Denver, CO (Accepted)
192. Miller M, Jefferson C, Eberhart L, **Horberg M**, “HIV and Chronic Comorbidities: Medication Adherence and Clinical Endpoint Covariation,” CROI 2023, Denver, CO (Accepted)
193. Barth S, Kulie P, Monroe A, **Horberg M**, Castel A, “Prevalence and Risk Factors for Post-Acute Sequelae of COVID among Persons with HIV,” CROI 2023, Denver, CO (Accepted)

#### **Abstracts and Oral Presentations Pending Presentation or Awaiting Disposition**

1. **Horberg M**, Jefferson C, Watson E, Fathi L, Kim S, Gebo K, Hogan B, Humes E, Althoff K, “Effects of HIV Status on Incidence of Post-COVID Conditions in Patients with SARS-CoV-2 (COVID-19),” CROI 2024, Denver, CO (Submitted)
2. **Horberg M**, Jefferson C, Watson E, Fathi L, Kim S, Gebo K, Hogan B, Humes E, Althoff K, “Evaluating The Effect of Vaccination on Post-COVID Conditions among Patients With and Without HIV,” CROI 2024, Denver, CO (Submitted)

3. Silverberg M, Levine T, Sarovar V, Lea A, Leibowitz A, **Horberg M**, Hare C, Luu M, Flamm J, Satre D, “Effectiveness of Electronic Screening for Substance Use, Depression, and Anxiety in HIV Primary Care,” CROI 2024, Denver, CO (Submitted)
4. Lam J, Hou C, Alexeeff S, Levine T, Sarovar V, Metz V, **Horberg M**, Satre D, Silverberg M, “Sleep Apnea in People With and Without HIV in Primary Care,” CROI 2024, Denver, CO (Submitted)
5. Coburn S, Althoff K, Achenbach C, Solasanti J, Crane H, Eron J, **Horberg M**, “Recent Kaposi Sarcoma Trends by Age and Race/Ethnicity Among Men with HIV in North America,” CROI 2024, Denver, CO (Submitted)
6. Althoff K, Hogan B, Wainberg M, Gebo K, **Horberg M**, Moore R, Parcesepe A, on behalf of the NA-ACCORD of IeDEA, “COVID-19-Related Shutdowns and Viral Suppression in the US and Canada,” CROI 2024, Denver, CO (Submitted)
7. Lang R, Humes E, Hogan B, Borowsky L, Lyass A, kim A, LaValley M, Cachay E, Crane H, Kim HN, So-Armah K, Triant V, **Horberg M**, Althoff K, “The Initiation of DAAs by ASCVD Score Among People With HIV With Hepatitis C Virus,” CROI 2024, Denver, CO (Submitted)

---

## PRESENTATIONS AND GRAND ROUNDS (selected)

---

1. “*Updated Recommendations for Primary Care for People with HIV*,” IDWeek, October 24, 2020, Washington DC
2. “*Sexual Health for Men who have Sex with Men*,” November 13, 2020, Kaiser Permanente Mid-Atlantic States, Washington, DC.
3. “*Transgender Health Care*,” November 5, 2020, Kaiser Permanente Mid-Atlantic States, Rockville, MD
4. “*Providing Culturally Competent Care to LGBTQ Populations in a Large Healthcare System*,” September 20, 2020, CDC STD Prevention Conference, Atlanta, GA
5. “*Kaiser Permanente Mid-Atlantic States’ Hepatitis Program*,” April 27, 2017; Centers for Disease Control and Prevention, Atlanta, GA
6. “*KP HIV Experience*”, MAPMG HIV CME, May 6, 2017; Kaiser Permanente Mid-Atlantic States, Rockville, MD
7. “*Kaiser Permanente Mid-Atlantic States’ Hepatitis C (KPMAS HCV) Program*,” June 18, 2014; Centers for Disease Control and Prevention, Atlanta, GA
8. “*Evaluating Effectiveness of HIV Care in Light of the Affordable Care Act (ACA)*”, November 26, 2013; Children’s National Medical Center, Washington, DC
9. “*Evaluating Effectiveness of HIV Care in Light of the Affordable Care Act (ACA)*”, November 1, 2013; Vanderbilt University, Nashville, TN
10. “*What’s Hot in HIV Clinical Research*,” IDWeek 2013 (43<sup>rd</sup> Annual Meeting of the Infectious Disease Society of America), October 2, 2013, San Francisco, CA
11. “*The Access to Care Committee Update*,” PACHA Public Forum at XIX International AIDS Conference, July 25, 2012, Washington, DC
12. “*Prioritizing HIV Care in the United States*,” Expert Session at XIX International AIDS Conference, July, 2012, Washington, DC

13. *"HIV Research in KP/GHC and the HMORN,"* HMO Research Network Annual Meeting, Seattle, Washington, May 1, 2012
14. *White House LGBT Conference on HIV/AIDS,* panel member, Atlanta, Georgia, April 19, 2012
15. *"HIV Care, Quality Metrics and Quality Outcomes: Kaiser Permanente and the HIV Challenge,"* Centers for Disease Control and Prevention HIV Division (invited presentation), Atlanta Georgia, April 11, 2012
16. *"HIV Care in Kaiser Permanente and the HIV Challenge,"* Presentation to the US Congressional HIV Caucus, Washington, DC, March 2, 2012
17. *"Making Chlamydia Screening a Priority in Medical Groups: Lessons Learned from HIV ,"* National Chlamydia Coalition Conference, Washington DC, January, 2012
18. *"Introduction to KP HIV Challenge,"* Center for Medicare and Medicaid Innovations Summit, Washington DC, January, 2012
19. *"HIV Care in Kaiser Permanente and the KP HIV Challenge,"* American Health Insurance Plans, February, 2012
20. *"HIV Research in Kaiser Permanente,"* NIH HIV Research Rounds, Bethesda, MD, September, 2011
21. *"Laboratory Monitoring for HIV+ Patients: What You Need to Know,"* 49<sup>th</sup> Annual Meeting of the Infectious Diseases Society of America, Boston, MA, October, 2011
22. *"The Development and Implementation of HIV Quality Measures and Implications for Care,"* Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, September, 2011
23. *"The Development and Implementation of HIV Quality Measures and Implications for Care,"* New York University Medical School, New York, NY, October, 2011
24. *"Optimized Multidisciplinary Care Teams Enhance Antiretroviral Therapy Adherence—What We Know,"* 6<sup>th</sup> International AIDS Society Satellite Symposium, Rome, Italy, July, 2011
25. *"Addressing Upstream Determinants of Treatment Access, Adherence, & Outcomes: Care Team Composition,"* 6<sup>th</sup> International Conference on HIV Treatment and Prevention Adherence, Miami, FL, May, 2011
26. *"HIV in the US in 2011...and Beyond,"* American College of Physicians Annual Meeting, San Diego, CA, April, 2011
27. *"HIV Care in KP in 2011...and Beyond,"* 7<sup>th</sup> KP HIV, Hepatitis, and STI Conference, April, 2011
28. *"Development of National and Multiagency HIV Care Quality Measures,"* Committee to Review Data Systems for Monitoring HIV Care, Institute of Medicine of the National Academies, February, 2011
29. *"Proposed and Continuing Metrics—NCQA and HEDIS,"* 2010 HIV National Summit on Diagnosis, Prevention, and Access to Care, Washington, DC, November, 2010
30. *Physician Issues in HIV Quality Measures,* Infectious Disease Society of America Annual Meeting, Vancouver, Canada, October 24, 2010
31. *HIV in the US and KP in 2010 and Beyond,* The Permanente Medical Group Division of Research Seminar, September 7, 2010

32. *HIV Quality Measures: National Development and in Kaiser Permanente*, American Medical Association-Physician Consortium for Performance Improvement, August 30, 2010
33. *Access to HIV Care and Private Insurance: Payment for Treatment—Kaiser Permanente*, National Academies Institute of Medicine Workshop on HIV Access to Care, Washington, DC, June 21-22, 2010
34. *KP HIV Program*, Presentation to Kaiser Foundation Health Plan National Leadership Team, Oakland California, June, 2010
35. *HIV in the US in 2010 and Beyond—Where We're Going*, American Conference on the Treatment of HIV, Denver Colorado, May, 2010 (opening plenary)
36. *Barriers and Facilitations to HIV Testing in Private Care Settings*, National Academies Institute of Medicine Workshop on HIV Testing, Washington, DC, April 15-16, 2010
37. *HIV Quality Measures as Part of National HIV/AIDS Strategy*, National HIV/AIDS Strategy Consultation, December 2009
38. *HIV Quality Measurement Through Electronic Health Records*, NCQA Policy Conference, December, 2009
39. *HIV in the World, US, and KP*, NABC Conference, July, 2009
40. Roundtable co-Chair, *Metrics and Evaluation Measures for Monitoring the Implementation of Routine HIV Testing*, April, 2009—final report available at [http://www.hivforum.org/storage/hivforum/documents/metrics/hiv\\_testing\\_metrics\\_report\\_12.14.09.pdf](http://www.hivforum.org/storage/hivforum/documents/metrics/hiv_testing_metrics_report_12.14.09.pdf)
41. HIV Testing in Managed Care or Large Health Systems, *Metrics and Evaluation Measures for Monitoring the Implementation of Routine HIV Testing*, April, 2009
42. Quality Measurement in HIV and Recommendations for Improvement, 6<sup>th</sup> National HIV/AIDS, Hepatitis, and STD Conference, April, 2009
43. What We Know and What We Don't Know about the Effectiveness of Implementing Routine HIV Testing: The Private Sector Perspective, *2008 National Summit on HIV Diagnosis, Prevention, and Access to Care*, November, 2008
44. Investigating HIV Quality Performance and Outcomes in Kaiser Permanente, Kaiser Permanente Northern California Division of Research, January, 2008
45. Clinical Trials in Managed Care Settings, Forum for Collaborative HIV Research, January, 2008
46. HIV Testing in Kaiser Permanente, Kaiser Permanente National Diversity Conference, November, 2007
47. HIV Antibody Testing, Kaiser Permanente Northern California Laboratories, September, 2007
48. Components of Care, KP National HIV, Hepatitis, and STD Conference, April, 2007
49. HIV 101 and HIV in KP, Center for Health Research, April, 2007
50. Expanded Access in Kaiser Permanente, Forum for Collaborative HIV Research, February, 2007
51. HIV Antibody Testing in Kaiser Permanente and Group Health Cooperative, *Opportunities for Improving HIV Diagnosis, Prevention, and Access to Care in the U.S.*, November, 2006
52. "HIV at 25: The KP Experience," Kaiser Permanente National Diversity Conference, October, 2006

53. LGBT Health Challenges, KP National Diversity Conference, November, 2000
54. Panel Discussion, Harvard University and AAHP, June, 1997—Physicians, Managed Care, and the Media
55. “Primary Care of the LGBT Patient”, Kaiser Santa Clara, June, 2002
56. HIV Care, KP national nursing update teleconference, 2000 and 2002
57. ABC’s of AIDS to Cupertino Union School District, January 1999

**CURRENT RESEARCH: M. HORBERG, MD, AS PRINCIPAL OR SITE INVESTIGATOR**

**ACTIVE**

75D30122D15463 Horberg (PI) 09/28/2022-09/27/2027

**Vaccine Safety Datalink (VSD) Project**

KPMAS has joined the VSD as the site for Mid-Atlantic. We will explore and report on vaccine safety and provide regular data updates for assigned projects and for advanced signal for new and established vaccinations. This is performed for all communities and age groups.

Role: Principal Investigator

75D30122C14191 Silverberg (PI) 09/01/2022-08/31/2027

US Centers for Disease Control and Prevention  
Kaiser Permanente Northern California

**Kaiser PrEP Data**

This will provide additional data and demographics to assess the United States’ use of HIV Pre-Exposure Prophylaxis and study the demographics and opportunities for its use within the USA.

Role: Site Principal Investigator

5U01AI069918-02 Horberg (PI) 05/01/2022-12/31/2023

National Institute of Allergy and Infectious Diseases

**North American AIDS Cohorts Collaboration on Research and Design (NA-ACCORD). Investigating PASC in integrated and non-integrated systems**

Purpose of the study are to compare PASC (Post Acute Sequelae of CoV-2-SARS)with accounting for pre-existing conditions and matching to COVID-negative population, comparing by HIV antibody status. Comparisons to another health system (Johns Hopkins Medicine) and by COVID vaccination status also will be studied. Initial investigation resulted in showing increased risk of PASC among patients with COVID, but also helped define the syndrome.

Role: Principal Investigator

R01HL160328 Silverberg and Satre (Co-PI) 08/15/2022-06/30/2027

National Heart, Lung, and Blood Institute through Kaiser Permanente Northern California

**Assessing Syndemics of Cardiovascular Disease in People with and without HIV**

This study will explore the role social demographic and community factors in the impact of HIV on heart disease and visa versa. It also will explore use of KP Research Bank to data and blood samples to explore the role of genetics in these morbidities.

Role: Co-investigator

R01AI175862 Marcus (PI) 09/21/2022-07/31/2027

National Institutes of Mental Health through Harvard Pilgrim Research Institute

**Cabotegravir PrEP: Actionable Robust Evidence for Translation into Practice (CABARET)**

This study will explore what factors contribute to employment of long-acting HIV Pre-Exposure Prophylaxis and how can this best be encouraged and grown in use to prevent HIV infection within an integrated care system.

Role: Co-investigator

10077

Horberg (PI)

08/01/2020-07/31/2024

Norwegian University of Science and Technology

**Genome-Wide Association Study of Bloodstream Infection Incidence and Mortality in the General Population**

This study explores the possibility of multiple gene mutations (both single and multiple) that could lead to increase risk of bloodstream infections and possibility of mortality. Dr. Horberg will oversee the use of the KP Research Bank data for the study.

Role: KP PI

R24AI152598

Castel (PI)

06/01/2020-05/31/2025

National Institute of Allergy and Infectious Disease

The George Washington University

**The DC Cohort: A Longitudinal Population-Based Cohort Study of People Living With HIV in Washington, DC**

The goals of this study are 1) enhance the Cohort database to incorporate new data sources to comprehensively describe and monitor HIV and co-occurring conditions; 2) expand the use of the existing DC Cohort Clinical Dashboard to monitor HIV care outcomes as well as key indicators related to ending the HIV epidemic; and 3) use the Cohort as a platform from which to develop pioneering interventions to improve the quality of care of people living with HIV.

Role: Co-Investigator and site PI

Kaiser Permanente Research Bank Horberg (PI)

01/01/2014-12/31/2023

**Kaiser Permanente Research Bank**

In this study, KP Research Bank aims to recruit 280K members total across all KP regions to increase the overall Research Bank collection to 500K. Members will be consented to provide a biospecimen and complete a survey. This region will participate in the recruitment and other Research Bank-related efforts, including scientific, strategic and operational.

Role: Principal Investigator and Site PI

5U01AI069918-02

Moore (PI)

09/01/2008-04/30/2026

National Institute of Allergy and Infectious Diseases

**North American AIDS Cohorts Collaboration on Research and Design (NA-ACCORD)**

This is the North America response to IeDEA, and for which KP Northern California and Mid-Atlantic States participates. It is a collaborative cohort compendium and analysis for purposes of achieving sufficient power to address issues that could not be adequately addressed by single cohorts.

Role: Site Principal Investigator and member of Executive Committee

5U01AA026230

Silverberg (PI)

09/15/2017-08/31/2024

National Institute of Health via Kaiser Permanente Northern California

**COMpAAAS Tripartite: ART-CC, KP, and VA**

The purpose of the overall study is to participate in a scientific collaboration across three grant partners to assemble data sets, including electronic health record data concerning HIV, especially related to cardiovascular disease and substance use, including alcohol.. Partners will interpret and disseminate results of the study through conference abstracts and manuscripts.

Role: Site Principal Investigator

**COMPLETED/INACTIVE**

R24AI152598

Castel (PI)

06/01/2021-05/31/2023

National Institute of Allergy and Infectious Disease

The George Washington University

**Measuring the Impact of COVID-19 among a Urban Cohort of PLWH in Washington DC**

Purpose is to better understand the interplay of COVID-19 among a population impacted by HIV infection within a defined population in Washington, DC.

Role: Co-investigator

5U01AI069918-S1 Moore (PI) 05/20/2020-06/30/2022  
National Institute of Allergy and Infectious Diseases  
**CIVETS of the North American AIDS Cohorts Collaboration on Research and Design (NA-ACCORD)**  
The purpose of this study is for the existing NA-ACCORD collaborators to share data collection instruments, algorithms for identifying COVID-19 disease, and analytic approaches to expedite answers to urgent questions in multiple data sources.  
Role: Co-Investigator

4291 Silverberg, Horberg (co-PI) 12/15/2017-12/31/2022  
Gilead, Inc.  
**HIV Infection, Use of Tenofovir and Other Antiretrovirals, and Risk of Fatal and Non-Fatal Comorbidities: Cohort study in Kaiser Permanente**  
The purpose of the overall study is to primarily compare the incidence rate of fatal and non-fatal comorbidities in HIV patients with incidence rates among matched HIV-uninfected controls, and HIV-uninfected individuals prescribed PrEP.  
Role: Multiple Principal Investigator

5756 Newman-Toker (PI) 05/15/2018 – 10/31/2020  
Gordon & Betty Moore Foundation  
**National Diagnostic Performance Dashboard to Measure and Track Diagnostic Error Using Big Data.**  
The goal of this study is to measure and track “missed diagnoses” of sepsis, stroke, and myocardial infarction and display information in ways that can be acted upon to reduce morbidity and mortality.  
Role: Site Principal Investigator

5R01DA043139 Silverberg (PI) 09/01/2016-7/31/2023  
National Institute on Alcohol, Abuse and Alcoholism  
**Implementing Computerized Substance Use and Depression Screening and Evidence-Based Treatments in an HIV Primary Care Population**  
The purpose of the overall study is to address the important topic of alcohol, smoking and other substance use and comorbidity screening and treatment among HIV-impacted patients. This study represents an important next step in the evolution of our top-quality HIV care in the context of an aging HIV patient population and has important implications beyond the Kaiser Permanente system.  
Role: Site Principal Investigator

R01HL132640 Silverberg (PI) 12/15/2016-11/30/2022  
National Heart, Lung, and Blood Institute  
**HIV Status and Incidence and Outcomes of Heart Failure**  
The overall purpose of this study is to work with our clinical and policy leaders in HIV and CHF care to quantify the risk of congestive heart failure (CHF) among HIV-infected patients, which antiretroviral therapy medications have increased risk for CHF and which may be protective, as well as develop care patterns for CHF among our patients with HIV.  
Role: Co-Investigator

1R01HL120894-01 Gold (PI) 05/15/2014-04/30/2019  
National Heart, Lung, and Blood Institute  
**SPREAD NET: Practices Enabling Adapting and Disseminating in the Safety NET**  
This is a study with Dr. Horberg (KPMAS) as site PI with Dr. Rachel Gold (Kaiser Permanente North West) as overall PI. Dr. Horberg’s role in this study is to mentor Dr. Gold on the study design and execution, as well as help derive and evaluate the performance metrics to be used in the study.  
Role: Site Principal Investigator

5UM1AI069503 Castel (PI) 12/01/2016-11/30/2020  
National Institute on Drug Abuse  
The George Washington University



**Terry Beirn CPCRA Clinical Trials Unit: A City-wide DC Cohort of HIV Infected Persons in Care in the District of Columbia**

The overall purpose of this study is to establish a clinic-based city-wide longitudinal cohort that will describe clinical outcomes in outpatients with HIV/AIDS receiving care in Washington, DC, with the goal of improving HIV/AIDS care in DC.

Role: Site Principal Investigator

GF001034

Adams (PI)

09/01/2017-8/30/2019

Garfield Memorial Fund

**Predictive Modeling to Aid Clinical Decision-Making and Improve Diabetic Peripheral Neuropathy**

This study aimed to create a model to predict who is more likely among patients with diabetes mellitus to need interventions to improve outcomes for diabetic neuropathy.

Role: Site Principal Investigator

CDRN-1306-04681

McGlynn (PI)

04/08/2014-10/06/2016

PCORI—PCORnet

Patient-Centered Outcomes Research Institute

**KP & Strategic Partners Patient Outcomes Research to Advance Learning (PORTAL) Network**

In this project, this region will collaborate with patients, clinicians, and operational leaders to develop the infrastructure necessary to create a highly functioning clinical data research network (CDRN).

Role: Site Principal Investigator

R01DA031059-01A1

Linan (PI)

06/15/2012-05/31/2017

National Institute on Drug Abuse

**Simulation Modeling to Improve HIV/HCV Screening, Treatment & Care**

The overall purpose of this study is for multi-institution, collaborative effort to construct a simulation model of HIV/HCV co-infection that includes HCV screening, linkage to care, loss to follow-up, and treatment for HIV and HCV.

Role: Co-Investigator

Care Management Institute

Horberg (PI)

01/15/2007-12/31/2020

**Kaiser Permanente HIV Quality Improvement and Performance Program**

We seek to determine quantitative measures of HIV care and outcomes in Kaiser Permanente, which has never been done on a systematic basis in a managed care organization previously. We seek to then initiate quality improvement programs where we determine there are opportunities for improvement.

Role: Principal Investigator

R21MH085553-01A1

Horberg (PI)

08/14/2009-07/31/2012

National Institutes of Mental Health

**Optimizing Multidisciplinary HIV Care Team for Maximal HAART Adherence**

Retrospective cohort study to determine optimized HIV multidisciplinary care team to maximize HAART adherence and other HIV outcomes and minimize urgent care utilization

Role: Principal Investigator

141-9127

01/15/2004-12/31/2007

NIAID Bridge Award

Horberg (PI)

**Epidemiology & Clinical Outcome of HIV/HCV Co-Infection**

This is a Kaiser Permanente program-wide analysis of an HIV+/HCV+ cohort, including testing rates, compared to the VA's program wide cohort and treatment rates of HIV+/HCV+ patients.

KPNC Community Benefits Research Fund Horberg (PI)

01/1/2010-12/31/2012

**Impact of Missed Office Visits on HIV Outcomes and Mortality**

A retrospective cohort study investigating the impact of missed office in the first twelve months after HIV diagnosis on later mortality, treatment adherence, and other HIV-related health outcomes. Comparisons will be made to the previously published work at University of Alabama, Birmingham.

Merck Laboratories

Horberg (PI)

08/01/2008-12/31/2012

**Considerations of Emerging Issues in the Treatment of HIV (“CEITH”)**

Retrospective cohort study investigating issues of low level viremia in patients on antiretroviral therapy, advanced treatment failure in HIV-infected patients, and uptake of a new antiretroviral drug class in a closed healthcare system.

115-9837

Horberg (PI)

01/1/2007-12/31/2010

KPNC Community Benefits

**Differences in Syphilis Incidence, Disease, and Treatment in KPNC HIV Infected and HIV uninfected Populations**

An epidemiologic analysis of syphilis disease among HIV-infected compared to HIV-uninfected patients since 1995 in KPNC. Disease stage, response to therapy, and recurrence of syphilis disease is considered.

115-9410

Horberg (PI)

01/1/2007-12/01/2010

Gilead Sciences

**Treatment Regimen, Provider, and Clinical Characteristics Associated with Receipt of HAART: An Analysis from Kaiser Permanente**

The goal of this retrospective cohort study using data from KPNC, KPNW, KPGA is to determine the predictors of initiating HAART therapy in the modern treatment era and has that changed over time.

115-9058

Shafer (PI)

09/12/2006-09/11/2011

Abbott Laboratories

**Economic Implications of Care of HIV-Positive Patients with Multi-Drug Resistance within a Managed Care Population (MDR)**

This retrospective study using cost and other data is to determine the added overall cost of patients who are on their third (or likely greater) HAART regimen compared to antiretroviral naive patients beginning their first regimen in the modern HIV treatment era.

Role: Co-investigator

115-9856

Horberg (PI)

10/16/2006-12/31/2010

Gilead Sciences

**Effect of Tenofovir on Renal Function--An Observational Cohort Study**

We will determine the incidence of change in renal function of patients taking TDF and compare that to patients on other NRTI. We will also attempt to determine if TDF preparation makes a difference (Viread vs. Truvada).

R01HS017528

Meenan(PI)

04/01/2010-01/31/2014

AHRQ

**Preventive Health Index for HIV-Infected Population**

Retrospective study to assess the impact of preventive health services on the ongoing and long term care of HIV-infected patients in KP. This work will extend the original work on the preventive health index by Tom Vogt, PhD. Data from KPNC, KPSC, KPNW, and KPGA will be utilized.

Role: Site Principal Investigator

**PENDING**

None.

**OVERLAP**

None.